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Abstract 
 
The incidence of malignant melanoma has increased steadily during the last decades. Large 
portions of individuals with this particular skin cancer develop multiple brain metastases, 
which is associated with a particular poor prognosis, and thus new therapeutic approaches are 
needed. Increased attention has been given lately in literature to the establishment of 
functional nano-scaled materials for applications in combined cancer therapy and diagnostics, 
a field termed «theranostics» or «theragnosis» (therapy + diagnostics).  
 
Recently, a collaborator at the Institute of Macromolecular Chemistry (Academy of Sciences, 
Prague) developed a multimodal nanoprobe, consisting of a backbone of glycogen. Two 
different contrast agents were encompassed in this, namely Dyomics-615-NHS ester, a 
fluorescent marker and Gd-DOTA, a well-known magnetic resonance imaging contrast agent. 
The nanoprobe can also be loaded with positron emission tomography tracers and therapeutic 
substances, and targeting may be achieved by loading the probe with antibodies. The 
nanoprobe has a great potential for being a theranostic probe, as the backbone consists of 
glycogen, which is regarded nontoxic to human cells. Further, magnetic resonance imaging 
and positron emission tomography may be used to evaluate drug uptake and treatment effects.  
 
Since this nanoprobe is completely new, it has not been tested previosly on human cell lines 
in vitro and in vivo. The main aim of the current Master thesis was thus to perform toxicity 
and viability studies in vitro, to determine the usefulness of the nanoprobe. The usability of 
the nanoprobe was evaluated on three different metastatic melanoma cell lines in vitro. 
Fluorescence microscopy and high throughput imaging revealed a high cell labeling efficacy 
with an optimal uptake period at 24 hours incubation time. Reduced cell viability was not 
found after labeling with the nanoprobe. In vitro magnetic resonance imaging studies of 
labeled cells casted in agar phantoms revealed that the nanoprobe also can be used as a 
contrast agent by this modality. The preliminary in vivo data indicated that tumor contrast 
uptake could be achieved in a subcutaneous tumor model. The promising results reported in 
this thesis may indicate that this nanoprobe can be used also for other cancer cell lines. 
Potentially, the nanoprobe can offer further benefits over established contrast agents used in 
magnetic resonance imaging, as pharmaceuticals attached to the probe can be traced 
simultaneously as the progression of disease and treatment are monitored.  
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 1 
1. Introduction 
 
1.1 Malignant melanoma: Incidence and biological aspects 
Malignant melanoma of the skin, hereafter referred to as melanoma, is an aggressive type of 
cancer, which originates from melanocytes located in the epidermis of the skin (1). During the 
past 50 years, a steadily increasing occurance has been detected globally and in 2008, the 
annual incidence was estimated to be 200 000 individuals worldwide (2). A considerable 
portion of these cases is manifested in fair-skinned populations in developed countries where 
USA, Australia and the Nordic countries present with the highest rates. In developed 
countries, melanoma is the sixth most frequent type of cancer, and 46 000 deaths are 
registered as a consequence of the disease every year (3). Although melanoma only accounts 
for 5 % of all skin cancers, it is responsible for 80 % of skin cancer related deaths (4, 5). The 
growing occurrence has been attributed to more frequent exposure to sun radiation, however 
this environmental risk factor is accompanied by skin phenotype and family history of certain 
inherited mutations (6).  
 
In general it often appears that the incidence of cancer occurs more frequently with increasing 
age (7). In Norway, individuals within the age group 50–70+ are most often afflicted (8). This 
is in orchestra with the statement above, conceivably due to an accumulation of somatic 
mutations and immune system regression with growing age (9, 10). In the case of melanoma 
however, the incidence in Norway unveils a peak at the age 15–49 for women and 25–49 for 
men (8). This suggests that a younger population is affected, which is in disagreement with 
the traditional idea of cancer mainly influencing the elderly.  
 
As in general carcinogenesis, melanoma is also presumed to develope in a stepwise pattern 
from a focal origin such as a precursor neoplasm. It has been suggested that the onset of 
malignancy is dependent on multiple mutations in several cell signaling pathways (Figure 1.1) 
(11). In melanoma development, it is often distinguished between radial and vertical growth 
phases as illustrated in Figure 1.1 (12). Radial growth is characterized by an in situ lesion 
with melanocytic growth occuring by cell proliferation horizontally in the basal layer of the 
skin (4). At this stage the cells have not transformed, and therefore do not have any cancer 
cell-related properties such as angiogenesis or ability to metastasize. Provided enough time, 
this phase may be substituted by vertical growth (Figure 1.1). During this juncture, the 
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neoplasm grows downward and penetrates dermis and a nodular or palpable lesion on the skin 
often occurs (4, 13). Accompanied with the vertical growth phase is an accumulation of 
multiple mutations (14), which challenges the prognostic power of genetic expression (15). 
The prognosis of melanoma is therefore dependent on clinical manifestation at the primary 
site, histological findings as well as the number, size and placement of secondary tumors (15).  
 
 
Figure 1.1: Melanoma progression. Subsequent of melanocytic proliferation, atypical nevus may 
form in the epidermis layer. This is an abnormal growth of melanocytes, which can result in a pre-
malignant lesion. Melanocyte proliferation will then take place horizontally in the skin, characterized as 
a radial growth phase, where tumor growth rarely occurs deep into dermis. After several possible 
cellular mutations, a vertical growth phase may take place, in which malignant melanoma cells invade 
the basement membrane while proliferating vertically. Subsequently, the melanoma cells can acquire 
further malignant properties enabling them to spread to distant organs such as lungs, brain and liver. 
Figure created with items from Somersault (16) and American Association for Cancer Research (17). 
 
Tumor thickness, as illustrated in Figure 1.1, was introduced by Alexander Breslow in 1970 
and measures the depth of the melanoma lesion in mm (18). In this system, the expected 
prognosis is reduced with increasing tumor thickness or depth. This is still used in the clinic 
today, as it is a reliable predictor of tumor invasiveness, metastatic potential and prognosis 
(4). 
 
1.2 The metastatic process with emphasis on brain metastases 
Metastasis can be described as a series of linked sequential steps in which cancer cells 
disseminate from their origin to a secondary site. A very frequently reported outcome for 
melanoma patients (75 %) is the formation of multiple brain metastasis (19-21), displaying 
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the highest tendency of any cancer to disseminate to the central nervous system (22). With a 
median survival estimated to a few months, secondary tumors to the brain consequently 
correlate with a low prognosis (19, 23).  
 
As melanoma neoplasms grow beyond ∼1 mm3, they depend on vascularization to receive 
oxygen and nutrients (24). At this point, hypoxia often occurs as a result of tumor growth, 
which triggers angiogenesis. Vascularization can be obtained by several mechanisms of which 
vascular co-option through pre-existing blood vessels and angiogenic sprouting from pre-
existing vessels are two examples (25-28). The initiation of tumor vascularization is a balance 
between proangiogenic and inhibiting factors, where vascular endothelial growth factor 
(VEGF) and thrombospondin-1 (TSP-1), respectively, are representative examples. Further 
vessel development depends on yet other proangiogenic factors, such as angiopoietin and Tie-
R (29). In addition to further tumor growth, angiogenesis also provides access to the 
vasculature which subsequently allows tumor cell dissemination (24). Prior to local invasion 
into dermis, migrating melanoma cells often acquire an epithelial-mesenchymal transition 
(EMT)-like phenotype characterised by altered cell-cell interaction properties (1). Normally, 
E-cadherins mediate melanocyte contact with five to eight surrounding keratinocytes. 
However, during melanoma progression this contact is lost by downregulation of E-cadherin 
(1, 30). In addition to this detachment of melanoma cells from its surroundings, altered 
cellular adhesive features are obtained, which enable them to attach to new sites (30). Local 
invasion includes the employment of different proteases to degrade extracellular matrix 
(ECM), such as matrix metalloproteinases (MMPs). Several components are involved in the 
simultaneous movement of melanoma cells, such as interacting integrins, components of the 
actin cytoskeleton and focal adhesion complexes (31). During degradation of ECM, cell 
motility and cell morphology is constantly altered (32). Melanoma cells often intravasate to 
the lymphatic or hematogenous circulatory system (33), in which they are subjected to 
immunological and mechanical barriers during transport to distant organs.  
 
Although melanoma cell dissemination can occur through lymphatogenous and hematogenous 
paths, the cells have to gain access to the blood circulatory system in order to extravasate into 
brain tissue. Once a subset of a migrating cell population reach a secondary organ, such as the 
brain, they may be trapped in for instance vascular branch points due to size restrictions or 
reduced flow in capillaries (Figure 1.2 A) (28).  
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Figure 1.2: Formation of brain metastases. Once a subset of the primary tumor manages to 
approach the brain, they are caught in vascular beds (a). Following extravasation (b), secondary 
tumors may grow further by preexisting blood vessels (c) or by employing angiogenesis (d). Adapted 
from Eichler, A.F. et al., 2011 (28), modified with larger fonts.  
 
Subsequent passage across the blood-brain barrier (BBB) depends on cellular adhesion to 
local endothelium before extravasation into the brain parenchyma is possible (33). The BBB 
is situated at the level of cerebral capillaries, and separates circulating blood from 
cerebrospinal fluid surrounding neuronal tissue. Movement of solutes and cellular elements 
are thus restricted from entering the brain parenchyma by this protective impediment. Despite 
this, certain types of cancer cells, such as from melanoma, manage to extravasate and 
subsequently create secondary tumors within the brain (34). After attaching to endothelial 
cells in the brain microvasculature, a remodeling of the capillary network occurs, and the 
tumor cells transmigrate through BBB and thus extravasate into the brain parenchyma (24, 
35). The exact mechanism for this is not known (36), but it has been suggested that the BBB 
might have a sustaining function in the formation of brain metastases (34). Previously, it has 
been reported that migrating melanoma cells located in capillaries often express the Ig family 
cell adhesion molecule L1CAM (37), mainly expressed in neuronal and cancerous tissue (38). 
Additionally, the sialyltransferase ST6GalNaC5 (39) has also been identified as a mediator of 
tumor cell transmigration through BBB (37, 40). Other proteins targeting specific organs 
might also be expressed by the tumor cells (36). Additionally, activation of integrins has been 
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proposed to influence endothelial tumor cell adhesion (28). Thus, extravasation of migrating 
melanoma cells through blood vessels may occur. Subsequent extravasation, secondary 
macrotumors may begin to form (Figure 1.2 B), termed colonization (24).  
 
Colonization in the new milieu is dependent on paracrine or autocrine signaling of the tumor 
cells to stimulate further proliferation, in which the «seed and soil theory» postulated by Paget 
is relevant. This theory proposes that the occurrence of brain metastases is not random, but 
instead certain tumor cells, «the seed», have an attraction or affinity to the new environment, 
«the soil». If the host tissue allows for tumor growth and cell proliferation continues, 
angiogenesis is induced by the same mechanisms as for primary site tumors (Figures 1.2 D 
and E) and the lesion grows further (41). For brain metastasis, secondary tumors either 
employ angiogenesis or grow along pre-existing blood vessels by co-option (28). In addition 
to secondary tumors to the central nervous system (CNS), other common sites secondary to 
melanoma are subcutaneous tissue, lymph nodes, lungs, liver and bones (42).  
 
1.3 Model systems to study cancer  
In order to study cancer cell dissemination and solid tumor growth, suitable model systems 
are necessary. Such systems should represent tumor growth seen in patients as close as 
possible. Several in vitro and in vivo culture systems have been developed in the past, and a 
few of these are described in this chapter.   
 
1.3.1 In vitro cell culture  
The current understanding of cancer has partly been derived from tumor cell lines developed 
from primary and secondary tumors (43). Such cultured cells have been extensively used 
within the field of biomedicine for a number of reasons: Essential cancer cell features such as 
proliferation and an abnormal karyotype are maintained, and the method can easily be 
implemented in different research layouts with varying purposes (22). By growing cells in a 
monolayer in cultured conditions, a controlled growth environment is provided, which 
enables regular observation of the sample (Figure 1.3 left). Despite these advantages, and the 
fact that the technique is easy to use and repeat, certain limitations of this in vitro assay 
should be emphasised. Because cell behaviour to a great extent depends on interactions within 
a 3D environment, this aspect is compromised when growing cells in monolayer on flat dishes 
(44-47). Still, cancer research is excessively reliant on monolayer or 2D cell culture (43, 48), 
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and it can be considered a good starting point for cell based research as well as standardized 
methods for drug screening. To address some of the limitations associated with monolayer 
culture such as altered protein expression (47), cell proliferation (45) and metabolism (44, 
46), 3D cell cultures or spheroid models can be implemented in experiment designs. These 
have been described as superior compared to monolayer cultures (43). Instead of adhesion and 
migration occuring in only 2D, cells cultured in 3D layouts have the ability to adhere, 
proliferate and migrate in an additional dimension (Figure 1.3 right) (48).  
 
 
Figure 1.3: Cell culture illustration. The left column illustrates how cellular growth in media occurs 
flat on a plastic dish, constricted to the x-y plane of a culture flask. The right column shows how cells 
seeded in for instance a two-layered agar layout are provided a 3D environment, which results in 
altered cell shape and growth pattern. Figure created with symbols from Somersault (16). 
 
 
Various 3D cell culture experiment designs exist (43), where the additional dimension is 
accompanied by an improved modeling of the real in vivo situation. It has been shown that 
cell signaling, cellular stiffness and shape differs between the two layouts, and it can be stated 
that 3D cultures offer more physiological conditions, more similar to an in vivo situation, for 
cell lines compared to monolayer cultures. For continous cancer cell lines, this implies that 
true tumor cell characteristics are mimicked for cellular spheroids with impaired access to 
oxygen and nutrients centrally, surrounded by adhered aggregates or clusters of additional 
cells (49). Several issues related to how the additional dimension in 3D cultures provide 
altered conditions, still remain to be properly explained. Still, it is known that 
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microenvironmental factors promote cell function, and these are modulated by different 
means in 2D and 3D cultures (48).  
 
1.3.2 Animal tumor models  
To study tumor development and predict therapeutic efficiency of novel pharmaceuticals in 
cancer research, several pre-clinical animal tumor models have been developed, mostly based 
on the use of small rodents. To grow tumors in mice for instance, extractions of tumor 
material such as continous cell lines are regularly injected into animals, either subcutaneously, 
into the organ of which the cells originated from (orthotopic) or into the blood stream 
(ectopic). Also, genetically engineered mice holding a particular genotype are often used as 
model systems (50). The discovery of T- and B-cell-deficient mice, nonobese diabetic severe 
combined immunodeficiency (nod/scid) (51), permits the transplantation of established in 
vitro cell lines or tumor biopsy material into immuno-deficient model mice, to efficiently 
reassemble solid tumors after a lagtime of a few weeks (50). Although such preclinical 
models mimic a real situation more closely than in vitro cell cultures (52), there are several 
factors that retain such techniques from being ideal. For instance, tumors often form more 
rapidly in animal models with a smaller latency period compared to a cancer patient in a 
clinical setting. Also, the use of nod/scid mice in itself can be a disadvantage, as tumor 
development after xenograft in immunedeficient organisms differs from cancer patients (52). 
Nevertheless, the combined knowledge of studies on animal tumor models have added 
increased understanding of the cancerous progression, given that the most suitable model 
system for the specific scientific problem is chosen (24).  
 
1.4 In vitro cell viability assays 
A variety of methods to assess viability of cultured cells and cytotoxity of certain compounds 
of interest exist (53). These should be sensitive, rapid and inexpensive (53-55), and are often 
subdivided into four groups depending on the method of measurement: Colonogenic, 
radioactive, colorometric and fluorometric (53, 56). Resazurin, which has been used since the 
1950s (55), has the advantage of being non-toxic (57), and it can be used both as a 
colorometric and fluorometric assay, of which it has been indicated that the latter gives more 
precise measurements (55). Resazurin holds a major change in perceived hue when used as an 
indicator on oxidation–reduction in human cells. Resazurin is intrinsically a weak fluorescent 
of purple color, but is reduced to the highly fluorescent pink resorufin. This transformation 
only occurs in metabolically active and thus viable and proliferating cells. Dead cells do not 
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have the same ability to perform this activity, and on this basis, the colored product correlates 
with viable cells in culture. It is therefore possible to use this assay to predict cytotoxicity of 
any compound of interest by reading off the results at wavelength 530-560 nm excitation and 
590 nm emission (54, 55, 57, 58).  
 
1.5 Preclinical cancer imaging  
The field of image sciences has proven to be incredibly valuable in cancer research, and has 
together with clinical observations contributed greatly to our comprehension of the 
development and treatment of malignancies (59-61). A large amount of preclinical imaging 
techniques to visualize cancer cells and tumors exist, ranging from in vitro methods at cellular 
levels, to sub-millimeter in vivo approaches. Each modality has its benefits and disadvantages, 
and a single technique alone does not posess all the required capabilities for complete 
detection. Therefore, the possibility of dual or multimodal signal reading from one common 
probe enables visualization of samples with more than one modality (62, 63). In the 
following, the imaging modalities used in this project will be discussed briefly.  
 
1.5.1 Light and fluorescence microscopy  
Varying microscopic approaches are widely used in cell biological research. The non-invasive 
nature of light microscopy together with the feasibility to introduce fluorochromes makes it 
the technique of choice for live-cell imaging (64). Light microscopes can be used to 
determine cell viability as well as depicting pathological cell conditions.  
 
In all its simplicity, light microscopes consist of a light source, magnifying lenses and often 
also an image acquisition unit (64). In addition, mercury lamps are often incorporated in 
widefield microscopes for excitation of fluorochromes and subsequent induction of emission. 
A bandpassfilter located between the light source and the cell sample efficiently restricts the 
range of excitation light. Because the emitted light has a longer wavelength than the excited, 
an emission filter (bandpass or longpass) is necessary between the detector and the cell 
sample. The excitation light is thus blocked, and the final image is prevented from distortions. 
The images are often detected by a charged couple device (CCD), and displayed on a 
computer screen (64).  
 
Fluorescence is a molecular characteristic of certain substances where light of a given 
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wavelength is absorbed, which transfers electrons to an orbital of higher energy, introducing 
an excited state. As electrons fall back into original energy states, excess energy is released by 
means of light at a longer wavelength and thus lower energy (Figure 1.4). The emitted light 
can be detected with the aid of optical filters in customized microscopes (64).  
 
 
Figure 1.4: The principle of fluorescence. When light of a given wavelength is absorbed, an atomic 
electron is transferred to an orbit of higher energy. After the lifetime of the fluorescence agent, this 
excited state is substituted by the original state as the electron falls back into its previous energy level. 
As this happens, excess energy is given off by means of a light photon at a different wavelength. 
Adapted form Ishikawa-Ankerhold, 2012 (64). 
 
Fundamentally, fluorescent agents or fluorochromes are used as potent contrast enhancers in 
microscopic imaging (64). Multi-fluorescent imaging is considered a significant tool to 
analyse cellular and biological events, which is further amplified by the expanding range of 
available fluorochromes (65). As emitted fluorescent light can be amplified to the microscopy 
detector, cellular structures can be visualized more easily than without fluorochromes. This 
relies on the effectivity of the system to pass light to either a CCD or photomultiplier tube 
(PMT), and simultaneously block excited light. Examples of fluorescent substances are green 
fluorescence protein (GFP), a reporter molecule that is intrinsically fluorescent, and Hoechst 
33342, often used to analyse DNA.  
 
Visualization of fluorescent agents can also be enabled with confocal microscopy. Laser 
scanning techniques are commonly used, in which a laser beam is focused onto the sample 
and scanning in the x-y plane occurs line-by-line. What sets confocal techniques aside from 
conventional fluorescence microscopes is a pinhole used to eliminate scattered light. 
Ultimately this provides high-resolution micrographs with the entire sample in focus (66).  
 
1.5.2 High throughput imaging (HTI)  
HTI, sometimes also referred to as high content screening (HTS), was introduced in the late 
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1990s, and established a potential for live-cell microscopy of large quantities of cell samples 
(e.g. in 96-well plates), implemented in automatic image acquisition sequences (65). HTI has 
the capability to acquire data on multi-parametric samples, such as several fluorescent 
markers, and also enables repeated image acquisitions over a defined time-span. Large-scale 
drug-screening research is often based on high throughput approaches, thereby improving the 
productivity dramatically (67). HTI techniques can thus acquire data on large numbers of 
samples in a less time-consuming process compared to conventional fluorescence 
microscopic methods, without losing valuable information at the level of single cells.  
 
1.5.3 Magnetic Resonance Imaging (MRI) 
MRI can be regarded a superior imaging modality, due to excellent soft tissue contrast. It is 
also considered a risk-free procedure for the patient, as MRI does not use ionizing radiation.  
 
The essential source of the MRI signal is based on the hydrogen nuclei or protons, which are 
abundantly present in tissue. Each proton is positively charged, and is also constantly 
spinning around its own axis. According to physics theory, a moving electrical charge of this 
kind generates a current, which in turn creates a magnetic field. Stated in other words, each 
proton generates its own magnetic field, and can be considered a small magnet. This magnetic 
field is also referred to as a magnetic moment. The orientations of all these protons in tissue 
are usually randomly directed, creating a net magnetic moment, which is zero. However, 
when an object such as a patient or animal is placed within the main magnet of an MRI 
system, the protons will align either parallell or anti-parallell with the main magnet field, B0, 
inside the scanner. The majority of protons will align parallell, as this requires the least 
energy. The difference between the number of protons aligned parallell and the number of 
protons aligned anti-parallell is usually very small. However, this difference increases with 
elevated magnetic field strength, and is the source for generating a signal which in the end is 
reconstructed to become part of the MR image (68).  
 
When the protons are put inside the strong magnetic field B0, they will move in a way called 
precession. This movement is similar to what is seen in a spinning top, as the protons wobble 
but do not fall over during spinning. Thus the sum magnetic field from these protons, which is 
now regarded a single vector M0, rotates around B0 with a precession frequency determined 
by the magnetic field, termed the Larmor frequency (69).  
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In order to detect a signal from the precessing protons, the protons need to be manipulated. 
Radiofrequency (RF) pulses are then switched on and off, with the purpose of forcing the 
protons to fall out of the alignment with B0. The disturbance occurs when energy with the 
same frequency as the precession frequency is applied to the tissue, a phenomenon called 
resonance. The net magnetic moment will as a consequence move out of alignment with B0, 
and the protons are moved into the transverse plane, or the x-y plane (Figure 1.5 B) (68).  
 
 
Figure 1.5: Relaxation after an RF pulse. The hydrogen protons are initially aligned with the main 
magnetic field, B0 (A). After the introduction of an RF pulse which manipulates the protons, the 
longitudinal magnetism will decrease and transverse magnetism (in x-y plane) is increased (B). When 
the RF puse is switched off, the protons will start to fall out of phase, and as the transverse 
magnetisation decreases, longitudinal magnetisation increases (C). The precession continues 
throughout recovery of longitudinal magnetisation (D). Regain of longitudinal magnetism is called T1 
recovery, and loss of transverse magnetism is called T2 decay. Adapted from Currie, 2013 (68), 
modified with figure text.      
 
The use of an RF pulse will move some of the protons from the parallell to the anti-parallell 
state, resulting in a reduction in overall longitudinal magnetism. Also the RF pulse makes the 
protons move in the same direction, or phase. The result is that a magnetisation occurs in the 
transverse plane, moves at the Larmor frequency and thus generates an alternating voltage 
that can be detected in antennas or RF coils placed within close proximity. This results in the 
formation of an MRI signal. When the RF pulse is deactivated (Figures 1.5 C and D), the 
protons will start to move out of phase and lose energy, termed «proton relaxation». This 
takes place in two ways; transverse magnetism is referred to as T2 or spin-spin relaxation, and 
longitudinal magnetism returns to the initial situation called T1 or spin-lattice relaxation. The 
speed at which T1 relaxation occurs is dependent on the properties of the surroundings. 
Therefore, different tissues or arrangements with hydrogen to other substances will produce 
different T1 relaxation times. The time constant T1 is the time it takes until longitudinal 
magnetism is regained to 63 % of its final value. T2 relaxation describes loss of in-phase 
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protons due to inhomogeneities within the local tissue and within B0. The time constant T2 
describes the time it takes before transverse magnetism is reduced to 37 % (68).  
 
Varying combinations of RF pulses and imaging parameters constitute different imaging 
sequences, broadly categorized into spin-echo and gradient-echo sequences. In this way, 
tissues can be weighted by different means, dependent on the purpose of the image sequence. 
The images are constructed with the aid of gradients in three dimensions: The slice-selection 
gradient, GSS, is applied in a short bandwidth of frequencies matching the larmor frequency. A 
slice within the biological object is then excited, the thickness of which is dependent on the 
steepness of the gradient. For spatial signal encoding, phase (GPH) and frequency (GFR) 
gradients are employed. The application of these enables the detection of signal in phase and 
frequency for location within the selected slice. This is repeated in several steps for the entire 
slice, with the GPH altered for each step. Thus, multiple signal echoes are acquired and stored 
in a raw data matrix termed K space, before this is Fourier-transformed to the spatial content 
of MR images (68). The image reconstruction process for MRI signal is a complex matter 
(70), of which a further description is beyond the scope of this thesis.  
 
1.5.4 MRI phantoms 
MRI phantoms can be used to evaluate the application of novel contrast agents (71). 
Favourable features of such phantoms include comparable relaxation times to biological 
tissue, temporal stability, low costs and that they are easily available and simple to handle 
(71). A range of different materials for this purpose exists, and water, agar and agarose, which 
is a purified form of agar, remain the most common (71, 72). Phantoms mimicking biological 
relaxation times can according to Yoshimura (2003) be obtained using concentrations of agar 
and agarose at 1.5-3 % and 0.8-4 %, respectively (73). Based on acquired image series of 
such phantoms, it is possible to calculate the MRI signal through signal equations, as well as 
T1 and T2 relaxation constants (71).  
 
1.6 Nanomedicine   
Normally, single image modalities such as for instance MRI or computer tomography (CT) 
with Gd or iodine-based contrast agents, respectively, are used to diagnose and study tumor 
progression. Nanomedicine, on the other hand, is the application of materials of nano-scale 
size, either for therapeutic or diagnostic purposes (74-76). Depending on the particular 
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nanomaterial used, several advantages may be obtained compared to conventional approaches 
in diagnostics and therapy: Multiple contrast agents or optical tracers can be integrated into 
one common probe, thereby featuring detectable agents during their biological paths when 
injected into model animals or patients. Also, by modifying such nanoprobes with for instance 
antibodies, they can be targeted to specific locations. It is also possible to use nanoprobes for 
enhanced therapeutic delivery. Therapeutic agents such as doxorubicin might be packed onto 
nanoprobes constructed to respond to certain stimuli, exemplified by acidic pH, to release 
drugs (74, 77). Thus, drug-delivery may be optimized, while undesirable effects of the 
treatment, such as toxicity, are minimized (63, 64).  
 
Recently, the term «theranostics» or «theragnosis» has been implemented to describe the 
combination of therapy and diagnostics using common nanomaterials, thereby introducing a 
new dimension in cancer research (62, 63, 74, 77). Combining signal detection by means of 
biomedical imaging with localized drug delivery is unique for nanomaterials (62). Varying 
substances are used to construct such probes, ranging from organic to non-organic materials 
(62, 74). Targeted nanomaterials are modified with surface peptides or antibodies specific for 
the target-cell, whereas passive nanomaterials are constructed so that their size does not 
contradict the enhanced permeation and retention (EPR) effect, which is often the targeting 
mechanism for passive nanomaterials (74). EPR is the result of the irregular vascularization 
and morphology of tumors, and thus abnormal transport dynamics. This often results in 
molecules of nano-scale size accumulation inside tumors (78).  
 
1.6.1 Novel glycogen nanoprobe  
In 2012, Filippov and colleagues at the Institute for Experimental Medicine in Prague 
developed a nanoprobe that consists of biodegradable glycogen (63). The present glycogen 
material originates from oyster and the nanoprobe is through dynamic light scattering (DLS) 
experiments found to have a dynamic radius (RH) of 54.4 nm. After initial construction of the 
probe, it was subsequently modified to encompass 3.19 weight percent (wt%) of the MRI 
contrast agent Gadolinium-DOTA (Gd) in addition to 0.33 wt% of the fluorescent marker 
Dyomics-615-NHS ester (Dyo-615). Gd is a paramagnetic contrast agent and the governing 
type used in clinical MRI (79). It has seven unpaired electrons, and because electrons have a 
great charge-to-mass ratio, Gd produces a major magnetic moment. It is a T1 agent, which 
means it produces bright areas of contrast enhancement in T1 image sequences. Gd is useful in 
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diagnostics of brain tumors, as the blood-brain barrier (BBB) often is compromised in the 
tumors and T1 agent thus leaks into the lesions (80). To reduce the toxic nature of Gd, it is 
chelated to different ligands, such as for instance DOTA used in our glycogen nanoprobe. Gd 
will affect the T1 value according to Figure 1.6 A.  
 
 
Figure 1.6: Illustrations of the contrast agents encompassed in the glycogen nanoprobe. A: MR image 
contrast expected to be found with the glycogen nanoprobe (T1 agent). Adapted from Chen, 2013 (77). 
Modified with ”no contrast” and larger fonts. B: Emission and excitation spectrum of Dyo-615. Adapted 
from Czerney, 2011 (81). Modified with larger fonts.  
 
The second segment of the probe, Dyo-615 is an indirect fluorochrome that emits light at 
wavelength 643 nm when excited by light with a shorter wavelength, and therefore higher 
energy, in accordance with Stokes shift (Figure 1.6 B). Thus, the probe can be used in a 
multimodal setting due to compatibility between MRI and fluorescence microscopy imaging.  
 
Furthermore, it is possible to attach therapeutic agents to the nanoprobe, which gives it 
potential as a theranostic unit. Although biodegradable, glycogen is not affected by amylases 
in the bloodstream, and the probe can thus be used as a passive nanomaterial via intravenous 
injection routes.  
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2. Aims  
 
Melanoma can be regarded a global and contemporaneously a national source of difficulty 
among relatively young individuals often awaiting a poor prognosis. It can thus be argued that 
further attention should be paid to the investigation of tumor spread and therapeutic 
efficiency. For this purpose the Translational Cancer Research Group at Department of 
Biomedicine, University of Bergen have developed animal models where cell lines derived 
from human melanoma metastases are injected into immunodeficient mice. This system 
closely mimics the dissemination observed in patients. Appropriate contrast agents are 
essential in this context, either to visualize single cancer cells or tumors within model 
animals. The superior goal of this Master thesis will thus be to describe applications of the 
theranostic glycogen nanoprobe presented in Chapter 1.6.1 for use in a metastatic melanoma 
model, which has not been done previously. Several imaging modalities will be used for this 
purpose, such as fluorescent light microscopy, high throughput imaging and MRI. If 
successful, this nanoprobe can offer additional advantages over established contrast agents in 
MRI, as it is possible to use it in a theranostic setting. Thus, by tracing the glycogen 
nanoprobe within a model animal or patient by MRI, it is possible to visualize where 
therapeutic agents attached to the probe are localized and also to monitor the progression of 
therapy. 
 
Four subaims have been defined within the work with this thesis:  
 
1. Use microscopy to demonstrate cellular internalization of the considered nanoprobe 
and subsequently conclude with an optimal dose for in vitro use  
2. Investigate cell viability after labeling cells with the nanoprobe, and study nanoprobe 
clearance from intracellular sites  
3. Verify the selected nanoprobe dose by scanning MRI phantoms with prelabeled cells 
to demonstrate reduced T1 relaxation times 
4. If time permits, test the nanoprobe on immunodeficient mice with tumors as part of a 
pilot in vivo experiment with nanoprobe doses matching Gd agents commonly used in 
a clinical setting 
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3. Materials and methods 
 
3.1 General cell culture work  
Three different metastatic melanoma cell lines were used in this project: Melmet 1 pGF1 
originates from a subcutaneous tissue extraction of a 36 year old female. Melmet 5 pGF1 is 
derived from a lymph node metastasis in a female at 56 years of age (82) and H1_DL2 is 
derived from a secondary tumor in the brain of a 38 year old female (52). All three cell lines 
were transduced with the genes for green fluorescent protein (GFP), whereas H1_DL2 also 
was transduced with the Luciferase Firefly gene. For confocal imaging as described in 
Chapter 3.2.4, H1 cells without GFP and Luciferase were used (52). Solutions and 
disposables frequently used for cell culture are listed in Table 1. 
 
Table 1: Equipment used for cell culture 
NAME SUPPLIER  
ALT DMEM: 
    450 mL Dulbeccos Modified Eagles Medium  
    50 mL Heat inactivated fetal calf serum (FCS)  
    10 mL L-Glutamine, 200 nM 
    10 mL Penicillin/Streptomycin (PEN-STREP), 100 µL/mL 
    16 mL Non essential amino acids 100X  
    0,1 mL Plasmocin 25 mg/mL  
 
Sigma-Aldrich Inc., MO, USA  
Fischer Scientific, MA, USA  
BioWhittaker, Verviers, Belgium   
BioWhittaker  
BioWhittaker 
Invivogen, CA, USA  
Dulbeccos phosphate-buffered saline (PBS)  Sigma-Aldrich Inc. 
Trypsin EDTA, 0.25 % BioWhittaker  
Freezing solution 1: 
    9 mL ALT DMEM + 1 mL FCS 
Freezing solution 2:  
    8 mL 1xPBS + 2 mL 100 % dimethyl sulphoxide (DMSO) 
 
 
 
Sigma-Aldrich Inc. 
Disposable pipettes: 5, 10 and 25 mL  Sigma-Aldrich Inc. 
 
The cell lines were cultured in monolayer with ALT DMEM growth medium and kept in an 
incubator at 5 % CO2 and 100 % humidity at 37° C. During experiment periods, the cells were 
regularly trypsinated and subcultured when almost confluent: After removing the old growth 
medium, the cells were washed with 0.03 mL/cm2 PBS followed by trypsination with 0.03 
mL/cm2 trypsin for approximately three minutes. Equal amounts of ALT DMEM were then 
added to inhibit further trypsin effects. For subculturing, approximately a third of the 
suspension was transferred to new culture flasks with blue filtered caps (25, 75 or 175 cm2, 
Nunc AS, Roskilde, Denmark) containing a total cell suspension/growth medium volume at 
0.2 mL/cm2. For storage over longer periods, the cells were cryopreserved and kept in liquid 
nitrogen at -196° C: After trypsination, 0.03 mL/cm2 ALT DMEM was added and the solution 
was resuspended before transferred to a 15 mL tube (Sigma-Aldrich Inc.). The cells were then 
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centrifuged at 900 rpm for four minutes. The supernatant was removed, and freezing solution 
1+2 described in Table 1 were added and the cell pellet resuspended. The cell solution was 
evenly divided between several 1 mL cryotubes (Thermo Scientific Inc., MA, USA). The 
tubes were kept at -80° C before they were placed in the nitrogen tank after 24 hours. For cell 
thawing, the cryotubes were retrieved from the nitrogen tank, spun down, the freezing 
solution was removed and the cells were placed in 25 cm2 culture flasks with 10 mL fresh 
growth medium. All work with cultured cells was done in sterile conditions, in a laminar flow 
cabinet bench.  
 
3.2 In vitro imaging experiments  
Despite the seeming multimodal advantage of the nanoprobe, it had not been tested 
previously on cancer cell lines. Different methods were thus developed for cell labeling with 
the nanoprobe prior to varying imaging experiments with microscopy and MRI. For all in 
vitro experiments, the glycogen nanoprobe was mixed 1:1 with autoclaved water (milliQ) to 
yield a stock solution of 1 mg/mL. All imaging experiments were performed using equipment 
at the Molecular Imaging Center (MIC), Department of Biomedicine, University of Bergen.  
 
3.2.1 Pilot project: Cellular internalization of the nanoprobe  
The Melmet 1 pGF1, Melmet 5 pGF1 and H1_DL2 cells were seeded in duplicate six-well 
plates (Nunc AS), each well with 105 cells in 2 mL ALT DMEM. The cell numbers were 
determined using a Countess Automated Cell Counter (Invitrogen, Paisley, UK), according to 
the manufacturers instructions. For each cell line, the cell suspension was diluted and 
distributed into each well of the six-well plate, and thereafter placed in a CO2 incubator. The 
next day the cells were labeled with the nanoprobe at concentrations 5, 10, 20, 50 or 100 
μg/mL. Cells in the remaining well in the six-well plate were not labeled and thus used as 
negative control (NC). After six hours of labeling in the CO2 incubator, the labeling solution 
was removed, and all wells washed with 2 mL preheated ALT DMEM.  The cells were then 
fixed by adding 2 mL 4 % paraformaldehyde (PFA, Thermo Scientific Inc.) in PBS to each 
well. The PFA was removed after 20 minutes, and replaced by 2 mL PBS. The same 
experimental setup as described above was used for the second plate after an incubation time 
with the nanoprobe for 24 hours. 
 
The six-well plates were then examined using a Nikon TE2000 inverted microscope (Nikon 
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Instruments Inc., NY, USA). A consistent study design was provided using the same objective 
magnification (20X), constant halogen illumination and the same setting on the correction 
collar (1.6) throughout the experiment. Observation of fluorescence signal from Dyo-615 was 
enabled through emissionMAX at 638 nm. The following exposure parameters were then used 
for the optical agents depicted: Fluorescence: Exposure time 2 000 ms and gain 1.7. Bright 
filter: Exposure time 2 ms and gain 1.2.  
 
The micrographs acquired during the pilot project were processed using Photoshop CS5 
(Adobe Systems Inc., CA, USA). To provide a realistic rendering of the images, the two 
layers were separated using NIS Elements Viewer (Nikon Instruments Inc.), which is the 
original software on the microscope. One image from each sample well was processed and 
presented in a collage created in Adobe Illustrator (Adobe Systems Inc.). Further, a method 
modified from Miller to study cellular fluorescence intensity was used (83). The fluorescence 
signal of four cells from four representative micrographs obtained in the pilot project were 
measured in Photoshop CS5 one by one. The bright field and fluorescence layers were opened 
in the software simultaneously. However, the lasso tool was used on the former layer alone to 
mark the region of interest, before the fluorescence layer was made visible in the same 
window. The histogram intensity value ranging from 0-255 for 8-bit images was then noted 
from the histogram overview. Cell morphology was also studied during image processing. 
 
Further we investigated whether cellular internalization of the nanoprobe occurred for all or a 
subset of cells in each sample. The images acquired during the pilot project were therefore 
investigated cell-by-cell, to detect fluorescence signal. Binary images were then created to 
demonstrate the findings. Appropriate threshold values were sequentially found for the 
brightfield and fluorescence layers in Matlab (The MathWorks Inc., MA, USA) for 
micrographs of each cell line captured of samples labeled with 5 μg/mL incubated for six 
hours. The Matlab command im2bw was used to find usable threshold values. Further, noise 
was removed from fluorescence micrographs of Melmet 1 pGF1 using the command 
bwareaopen. The resulting binary layers were then superimposed in Photoshop.   
 
3.2.2 HTI experiments: Determination of suitable nanoprobe doses   
All three cell lines were grown in 175 cm2 culture flasks until ∼80 % confluence. The cells 
were trypsinated and counted as previously described. For each cell line, 100 μL cell solution 
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was distributed into each well of a 96-well plate (Nunc AS), at the following concentrations: 
103 or 2·103 cells per well for the Melmet 1 pGF1 and Melmet 5 pGF1 cell lines, and 2·103 or 
4·103 cells per well for H1_DL2 cells. The plates were incubated for 24 hours. The glycogen 
nanoprobe was diluted in ALT DMEM to the concentrations shown in Table 2 and preheated 
before the growth medium in each well was replaced with labeling solution. The incubation 
times were 2, 4, 6 or 24 hours. 
 
Table 2: Overview of the 96-well plate layout used for the HTI experiments. Glycogen nanoprobe 
concentrations are presented in [µg/mL] and the different cell populations are indicated in the lower 
row. The column to the left, T (h), illustrates incubation time of the respective row with glycogen 
nanoprobe in hours prior to imaging. Abbreviations: NC: negative control, T: time, h: hours.   
 
  1 2 3 4 5 6 7 8 9 10 11 12 T (h) 
A PBS PBS PBS PBS PBS PBS PBS PBS PBS PBS PBS PBS   
B PBS 100 200 300 400 NC NC 100 200 300 400 PBS 2 
C PBS 100 200 300 400 NC NC 100 200 300 400 PBS 4 
D PBS 100 200 300 400 NC NC 100 200 300 400 PBS 4 
E PBS 100 200 300 400 NC NC 100 200 300 400 PBS 6 
F PBS 100 200 300 400 NC NC 100 200 300 400 PBS 6 
G PBS 100 200 300 400 NC NC 100 200 300 400 PBS 24 
H PBS PBS PBS PBS PBS PBS PBS PBS PBS PBS PBS PBS   
  103 or 2·103 cells per well 2·103 or 4·103 cells per well   
 
Before starting the HTI experiments, the labeling solution was removed, and each well was 
washed with preheated (37° C) ALT DMEM. Cellular nuclei were labeled by adding 100 μL 
preheated Hoechst 33342 (10 mg/mL, Thermo Scientific Inc.) diluted 1:5000 in PBS, into 
each well. The cell samples contained three different fluorescent agents; GFP, Hoechst and 
Dyo-615. The imaging acquisition was thus adjusted to capture these channels. The 96-well 
plates were examined one by one using the filters and exposure parameters listed in Table 3.  
 
Table 3: Filters and exposure parameters used during image acquisition. (Abbreviations: GFP: Green 
fluorescent protein, Dyo-615: Dyomics-615-NHS ester, LP: Long pass.) 
  GFP Hoechst Dyo-615 
Excitation (lamp) 488/510 (A) 360/410 (A) 560/655 (B) 
Emission filter 515 LP 435 LP 645/675 
Exposure time (s) 0,04 0,025 0,06 
Gain 0 0  10 
 
The image acquisition sequence on BD Pathway 855 (BD Biosciences, CA, USA) was then 
activated, and the utilized sections of the 96 plates including four stiched images and three 
channels per well was finished automatically approximately 45 minutes later. For each cell 
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line, 720 images were acquired in total from the BD Pathway system. To extract information 
from these numerous images, a pipeline in CellProfiler (Whitehead Institute for Biomedical 
Research, MA, USA) was created to automatically interpret the data. After creating an 
overview image with all wells, mean cellular fluorescence intensity was measured in the 
following way: The pixel values in all images were scaled from zero to one, by dividing all 
the pixels in the red image channel by the maximum possible intensity value. Further, all 
intensity measurements were computed from the aggregate of all the pixels of interest using 
these scaled values. The mean value presented in the chapter of results is therefore the 
average intensity value of all pixels in the red image channel.  
 
3.2.3 In vitro MRI: Verification of nanoprobe doses from HTI experiments 
Prior to in vitro MRI scanning, the three cell lines were embedded in 2 % Difco Agar Noble 
(BD Biosciences) in 2 mL Eppendorf tubes (Eppendorf AG, Hamburg, Germany). For each 
cell line, two sets of phantoms were created: One set contained cells prelabeled in monolayer 
with the nanoprobe, using the doses used for the HTI experiments. The second set contained 
unlabeled cells.  
 
2.2 · 106 cells were seeded into 175 cm2 culture flasks, and incubated for 24 hours. Each flask 
was then labeled with 200 μg/mL glycogen nanoprobe in 20 mL ALT DMEM, and incubated 
for another 24 hours.  
 
2.0 g Difco Agar Noble was mixed with milliQ in a glass bottle to a total volume of 100 mL 
(2 % solution), and heated in a microwave oven until boiling. The agar was then transferred to 
a preheated waterbath (50° C). Meanwhile, six different cell concentrations were prepared for 
each cell line, labeled and unlabeled cells, as listed in Table 4.  
 
The cell solutions were kept in 15 mL tubes in the CO2 incubator for ten minutes together 
with empty eppendorf tubes and disposable pipette tips. The tubes with cell suspension were 
then retrieved from the incubator one at a time, and carefully resuspended before 1 mL agar 
solution and 1 mL cell solution sequentially was added to an eppendorf tube. Immediately 
after, this mix was carefully resuspended to disperse the cells evenly, without introducing air 
pockets into the tubes. The tubes were then placed directly on ice for approximately ten 
minutes to allow the mix to congeal, before refrigerated prior to MRI scans. 
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Table 4: Overview of the MRI phantoms with varying cell concentrations. Each row in this 
table correspond with two eppendorf tubes with agar-casted cells per cell line; one tube 
containing labeled cells, and one tube containing unlabeled cells. The latter group was used 
as NCs for the associated test tubes.   
Cells in total per eppendorf tube Cell concentration 
6 · 106 3 000 cells/µL 
3 · 106 1 500 cells/µL 
1,5 · 106   750 cells/µL 
0,5 · 106 250 cells/µL 
0,1 · 106 50 cells/µL 
0,05 · 106 25 cells/µL 
 
Five additional tubes were included as control phantoms: One with 2 % stock agar solution 
(I), one with 1:1 2 % agar and ALT DMEM (II), one with 1:1 glycogen nanoprobe stock 
solution with 2 % agar (III), one with 1:1 water and 2 % agar (IV), and one containing only 
water (V).  
 
The phantoms were examined five at a time, using a 7 T small animal MRI scanner (Bruker 
Biospin MRI GmbH, Ettlingen, Germany). These were fixed inside a 40 mm quadrature 
volume coil and adjusted to align with the isocenter of the bore. An overview scan (TriPilot) 
was first completed, which provided an overview in sagittal, coronal and axial planes, to 
verify placement of the eppendorf tubes in the center of the magnet. This was followed by a 
turbo spin echo scan (TurboRARE_T2), which provided axial slices through the sample (TR: 
4000 msec, TE: 48 msec, FOV: 2.0 cm, Matrix: 256x256, Slice thickness: 1 mm, Number of 
slices: 15, Number of Excitations (NEX): 4 and Flip Angle (FA): 180°, scan time: 4 minutes). 
After visually inspecting the image series to decide on the superior image with respect to 
homogeneity of the scanned material, this image was chosen for further investigations by 
means of T1 and T2 mapping (TR: 5000, 3000, 1500, 800, 400 and 200 msec TE: 11, 33, 55, 
77 and 99 msec, FOV: 3.5 cm, Matrix: 256x256, Slice thickness: 1 mm, Number of slices: 1, 
NEX: 1, FA: 180°, scan time: 17 minutes). A region of interest (ROI) was defined around 
each phantom within the selected axial slice using image sequence analysis (ISA), each 
approximately covering 75 % of each tube.  
 
3.2.4 Confocal imaging: Intracellular location of the nanoprobe  
1.5 · 105 H1 cells were distributed into a 14 mm glass bottom in a 35 mm microwell dish 
(MatTek Corporation, MA, USA) and kept in CO2 incubator until cellular attachment to the 
coverglass had occured. The growth medium was then replaced by 1.5 mL glycogen 
nanoprobe in ALT DMEM at a concentration 200 μg/mL. The next day, the cells were stained 
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with preheated 150 nM MitoTracker® Green FM (Invitrogen) and incubated for 30 minutes. 
After removing the staining solution, 1.5 mL preheated Hoechst 33342 diluted 1:5000 in PBS 
was added to each well. After 20 minutes, the Hoechst solution was removed and replaced by 
preheated ALT DMEM in all wells. The live cells were then examined using Leica TCS SP5 
(Leica Microsystems, Wetzlar, Germany) with a 63X 1.4 oil lens and laser powers: Hoehcst 
33342 39 % 405 nm, Dyo-615 31 % 633 nm and MitoTracker 40 % 488 nm.  
 
3.2.5 Monolayer wound healing assay: Cellular migration  
A wound-healing assay was carried out to observe cell migration while exposed to the 
glycogen nanoprobe. A silicone culture insert (Ibidi GmbH, Martinsried, Germany) was 
inserted in each well in a 15 μ-slide 4 well chamber (Ibidi GmbH) so that they aligned with 
one another. A cell concentration at 4·105/mL was prepared for Melmet 1 pGF1 cells and 70 
μL of this cell solution was added to each bilateral gap of the culture insert. The plate was 
then incubated for 24 hours. The next day, the culture insert was carefully pulled away using 
sterile tweezers, to reveal a 500 μm (±50 μm) wound in the bottom of the cell monolayer dish. 
All chambers were then washed with preheated ALT DMEM. The test chambers were filled 
with 500 μL glycogen nanoprobe in growth medium corresponding to 200 μg/mL, and NC 
chambers filled with 500 μL ALT DMEM. Immediately after, cell migration into the wound 
was studied by time-lapse microscopy for 20 hours, using a Nikon TE2000 inverted 
microscope equipped with an incubator holding 37 0C, 100 % humidity and 5 % CO2. Several 
wound edge locations were selected for focus in x, y and z directions before the experiment 
was initiated. Micrographs of each well were captured every 15 minutes. 
 
All micrographs captured of labeled and unlabeled cells at every second hour until confluency 
were then quantified using FIJI (84). An erosion morphology filter was first added to the 
micrographs, before edges were found and the entire image sharpened. Black and white 
threshold was then applied, before the edges were detected again, and the look-up table (LUT) 
was inverted. By using the analysis function it was possible to outline the edges of the created 
mask and measure the wound size.   
 
3.2.6 Duration of cellular fluorescence: Nanoprobe clearance  
We then studied how long the cells kept their fluorescence after being stained and 
simultaneously monitored cell proliferation of labeled and unlabeled cells. All three cell lines 
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were thus studied in two separated layouts: The Melmet 1 pGF1, Melmet 5 pGF1 and 
H1_DL2 cells were seeded into two wells each per six-well plate at a concentration of 1·105 
cells/2 mL ALT DMEM. Five six-well plates were prepared in this manner. 24 hours later, 
cells were labeled with 200 μg/mL glycogen nanoprobe, whereas unlabeled cells were used as 
negative controls. The next day, the contrast agent added the day before was removed and 
exchanged with 2 mL preheated ALT DMEM in each well. Cellular fluorescence intensity 
was then captured using Nikon TE2000 at 0, 24, 48, 72 and 96 hours after removal of the 
nanoprobe. The same exposure parameters as described for the pilot project were used 
(Chapter 3.2.1). Cellular fluorescence intensity was measured as described in the pilot project.  
 
The same layout of six-well plates was used for monitoring cell proliferation under constant 
exposure to 200 μg/mL glycogen nanoprobe. All cells were then trypsinated and live and dead 
cells were counted for labeled and unlabeled cells at the same time points as for imaging 
experiments. The proliferation assay was done in triplicate.  
 
3.2.7 Soft agar assay: Investigation of the cells in a 3D environment 
A two-layered soft agar assay was used to study the cells in a 3D environment. The base agar 
layer was prepared first: Difco Agar Noble (BD Biosciences) was mixed with milliQ water to 
a 2.4 % solution and microwaved until dissolved. Further it was placed in a preheated 
waterbath at 50° C together with 30 mL ALT DMEM. When the temperature had stabilized at 
50° C (after approximately 10 minutes), agar and medium were mixed together 1:3 and 1.5 
mL of the solution was then pipetted onto each chamber in a six-well plate and cooled.  
 
The soft agarose overlay was subsequently assembled: 2.4 % low-melting-point agarose 
(Sigma-Aldrich) was made with milliQ and microwaved until dissolved. The mix was then 
kept in 50° C waterbath together with 30 mL ALT DMEM for 10 minutes. The agarose 
solution was then mixed 1:3 with growth medium, placed back into the waterbath and the 
temperature was decreased to 40° C.   
 
Meanwhile, cell solutions were prepared at a concentration of 8·104 cells/mL in growth 
medium. These cells were 24 hours in advance labeled with glycogen nanoprobe in 
monolayer, as described for in vitro MRI experiments. After trypsination and dilution, the 
cells were kept in 15 mL tubes in the CO2 incubator for ten minutes together with disposable 
pipette tips. For each cell line, the cell suspension was mixed 1:1 with low melting point 
 24 
agarose before 1.5 mL was administered over the base agar in the six-well plates, and put into 
a refrigerator for 30 minutes. 2 mL ALT DMEM was then overlayed the low melting point 
agarose, and the six-well plates were incubated for 14 days before the cells were scored for 
colony formation. The soft agar assay was repeated three times.   
 
3.3 Resazurin assay: Cell viability  
A resazurin assay was used to study cell viability during exposure to the nanoprobe, in which 
measured metabolism of labeled cells was compared to unlabeled. Four 96-well plates (Nunc) 
per cell line were prepared with 5·103 cells/well. An additional plate with ALT DMEM 
without cells was also prepared. After 24 hours of incubation, nanoprobe was added to the 
wells in concentrations of 100, 200, 300 or 400 μg/mL. Unlabeled wells were used as NCs.  
After another 24 hours of incubation, one column of each dose and cell line was used for 
viability sampling: Resazurin solution (0.1 mg/mL, Sigma-Aldrich) was added at a volume 
corresponding to 10 % of the volume of medium within each well. This was followed by 
signal read-out using a multilabel counter platereader (Perkin Elmer, Turku, Finland) after 4 
hours. The next day, a new row was added resazurin and measurements sampled in the same 
manner. This was repeated for five days in total to study cell viability after elevated 
incubation times with the nanoprobe. After each step of measurements, cell viability was 
visually confirmed well by well using an in-lab light microscope. The obtained measurements 
were in relative fluorescence units (RFUs) and based on six parallels.  
 
3.4 Pilot in vivo experiments 
We performed a pilot animal experiment to determine the suitability of the nanoprobe in vivo. 
The National Animal Research Authority approved all animal procedures. 12 weeks old 
female nod/scid mice were injected subcutaneously with 1·106 H1_DL2 cells in the left upper 
thigh (two animals), or the neck region and the left upper thigh (three animals) as illustrated 
in Figure 8. The animals were then kept in the animal facility under standard conditions; 
being fed a standard pellet diet and provided water ad libitum.   
 
After two and four weeks, bioluminescence imaging (BLI) was performed to assess tumor 
development and growth. Briefly, anaesthetized mice were injected intraperitoneally with D-
luciferin (150 mg/kg) 10 min prior to whole body imaging, performed with an Optix® MX2 
Small Animal Molecular Imager (ART Inc., Saint-Laurent, QC, Canada). Bioluminescent 
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images were acquired with Optix® OptiviewTM (ART Inc.) acquisition software (version 
2.00) and analysed using Optix® OptiviewTM (version 2.00.01, ART Inc.). ROIs were 
defined over each injection site and the emitted signal was detected at 560 nm. The 
pseudocolor intensity format was then calibrated for all images.   
 
Figure 3.1: Subcutaneous tumor cell injections into five nod/scid mice. All mice received one injection 
into their left flank; over the upper thigh and apart from the back and abdomen (A), whereas two of 
these additionally received one injection administered to their necks as well (B).  
 
For in vivo use, 15.7 mg of the glycogen nanoprobe was mixed with 1 mL physiological NaCl 
(0.9 %) to yield a solution containing 0.1 mmol Gd, corresponding to the concentrations of 
the T1 reducing contrast agent Omniscan (GE Healthcare, Fairfield, CT, USA). Each animal 
was first studied with one of the contrast agents, and after 24 hours the same animal was 
studied using the other contrast agent. A 40 mm quadrature volume coil was mounted onto 
the table together with a bed tip. Followed by a Tripilot, T2 scans were performed in axial and 
coronal orientations (TR: 4300 msec, TE: 36 msec, FOV: 4 cm, Matrix: 256x256, Slice 
thickness: 1.5 mm, Number of slices: 25, NEX: 3, Scan time: 7 minutes). T1 scans were then 
performed before and immediately after contrast agent administration (TR: 600/1000/1200 
msec, TE: 9 msec, FOV: 4 cm, Matrix: 256x256, Slice thickness: 1.5 mm, Number of slices: 
11, NEX: 6, Scan time: 4 minutes). Signal intensities within tumor ROIs were then compared 
on the T1 weighted MR images obtained after contrast injections.  
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4. Results  
 
4.1 Pilot project: Cellular internalization of the nanoprobe 
The pilot project was primarily done to demonstrate cellular internalization of the glycogen 
nanoprobe. In addition, cellular fluorescence intensity as a function of incubation time and 
dose was also discerned. The micrographs obtained using Nikon TE2000 in the pilot project, 
clearly demonstrated that the nanoprobe was internalized in the three cell lines used. This was 
manifested by fluorescence signal observed from the cytoplasmic segments of cells, through 
light emission detected at wavelength 643 nm. The results are presented in Figures 4.1-4.3. 
All images were captured with a 20X objective.  
 
 
Figure 4.1: Micrographs of Melmet 1 pGF1 cells labeled with the nanoprobe for six (A) and 24 hours 
(B). The different nanoprobe concentrations are presented on each image (ranging from 5 to 100 
µg/mL). A negative control (NC) is included to the lower right. Scalebar: 100 µm. 
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Melmet 1 pGF1 cells displayed a broad lamellipodium and an independent growth pattern for 
labeled and unlabeled single cells. It was observed that the degree of fluorescence increased 
with elevated dye concentration administered to the Melmet 1 pGF1 cells (Figure 4.1). The 
fluorescence intensity also increased with longer incubation times, which can be seen when 
comparing the corresponding samples in Figure 4.1 A and B. This was in particular true for 
the highest dose (100 μg/mL).   
 
 
Figure 4.2: Micrographs of Melmet 5 pGF1 cells labeled with the glycogen nanoprobe for six (A) and 
24 hours (B). The different nanoprobe concentrations are presented on each image (ranging from 5 to 
100 µg/mL). A negative control (NC) is included to the lower right. Scalebar: 100 µm. 
 
The Melmet 5 pGF1 cells held a star-like morphology with elongated filopodia and presented 
with a growth pattern in patches. Similar to the Melmet 1 pGF1 cells, it was noted that the 
cellular fluorescence intensity increased with higher nanoprobe doses and extended 
incubation times for Melmet 5 pGF1 as well (Figure 4.2).  
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Figure 4.3: Micrographs of H1_DL2 cells labeled with the glycogen nanoprobe for six (A) and 24 
hours (B). The different nanoprobe concentrations are presented on each image (ranging from 5 to 
100 µg/mL). A negative control (NC) is included to the lower right. Scalebar: 100 µm. 
 
The micrographs of the third cell line, H1_DL2 (Figure 4.3), revealed cell morphology 
similar to Melmet 5 pGF1 cells. Increased fluorescence intensity was manifested with higher 
doses and elevated incubation times. Compared to Melmet 1 pGF1 and Melmet 5 pGF1, it 
seemed to be a stronger fluorescence signal from the H1_DL2 samples at the highest doses; 
50 and 100 μg/mL glycogen nanoprobe (Figure 4.3).  
 
In general, it was observed that increased incubation times had great impact on cellular 
fluorescence intensity for all three cell lines investigated. This was particularly the case for 
doses above 50 μg/mL, whereas the lower doses did not result in distinctly increased 
intensities. To verify the visually observed increase in fluorescence intensity as well as the 
individual tendencies and differences for the three cell lines studied, all micrographs acquired 
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during the pilot project were quantified as described in Chapter 3.2.1. The average value from 
all measurements is presented in Figure 4.4, where intensities found in micrographs acquired 
after six and 24 hours incubation time with the glycogen nanoprobe are displayed. 
Corresponding cell lines and nanoprobe doses at the two time points were compared 
statistically using a two-tailed Students t-test and presented over the graphs in Figure 4.4 B.  
 
 
Figure 4.4: Fluorescence intensity graphs of Melmet 1 pGF1, Melmet 5 pGF1 and H1_DL2. The 
measurements were done in four representative images corresponding to Figures 4.1-4.3. Cells were 
incubated with glycogen nanoprobe for six hours (A), and 24 hours (B). The fluorescence level shown 
on the y-axis ranges from 0-255. A random single cell from each set of images is placed above each 
graph. Abbreviations: *: <0,05, **: <0,01 and ****: <0,0001. Mean ± standard deviation (SD).  
 
From Figure 4.4 it is noted that all measurements at 24 hours incubation time were 
significantly higher than the corresponding measurements at six hours. No major difference 
between cell lines was according to Figure 4.4 A registered beneath a nanoprobe dose at 20 
μg/mL. For all other measurements, a pattern is manifested in which Melmet 1 pGF1 cells 
display the lowest fluorescence intensity, Melmet 5 pGF1 cells in between and H1_DL2 cells 
the highest, suggesting that this cell line is easier to label than the other two. Two-way 
ANOVA for 4.7 A and B gave p-values <0.0001 and =0.0002, respectively. 
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As a final study in the pilot project, we investigated whether all or only a subset of the cells 
within each sample had internalized the nanoprobe. For nanoprobe doses below 10 μg/mL at 
six hours incubation time, we estimated a labelling efficiency at 99.865 % for Melmet 1 
pGF1, 99.932 % for Melmet 5 pGF1 and 100 % for H1_DL2. All samples above this dose, 
and all doses at incubation time 24 hours, showed a 100 % labeling efficiency. To display the 
findings, binary images of the samples containing the lowest nanoprobe doses (5 μg/mL) for 
the shortest incubation time period (6 hours) were created using Matlab as shown in Figure 
4.5.  
 
 
Figure 4.5: Binary images of Melmet 1 pGF1, Melmet 5 pGF1 and H1_DL2. The top row 
demonstrates the starting point for processing of binary images; brightfield microscope images with 
fluorescence layers superimposed. The middle row displays the corresponding binary images with 
black backgrounds, whereas the lower row an inverted version of the same image. Yellow or blue 
arrows demonstrate a single Melmet 1 pGF1 cell without fluorescence signal (Threshold values: 
Melmet 1 pGF1: Brightfield: 0.37, fluorescence: 0.067, Melmet 5 pGF1: Brightfield: 0.075, 
fluorescence: 0.08, H1_DL2: Brightfield: 0.45, fluorescence: 0.07).  
 
Figure 4.5 demonstrates 100 % labeling efficiency for all Melmet 5 pGF1 and H1_DL2 cells, 
whereas one Melmet 1 pGF1 cell does not display any fluorescence signal (yellow/blue 
arrow). The fluorescence signal within cytoplasm of Melmet 1 pGF1 cells was in general 
more dispersed compared to the other two cell lines. A sporadic appearance of multinucleated 
Melmet 5 pGF1 and H1_DL2 cells was registered, both for labeled and unlabeled cells. 
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4.2 HTI experiments: Determination of suitable nanoprobe doses  
As cellular internalization of the nanoprobe was confirmed, the next goal was to decide a 
suitable dose for use in further experiments. The results in Chapter 4.1 showed a relatively 
weak staining for the Dyo-615 segment of the nanoprobe for the given concentrations. Thus 
all images had to be adjusted for exposure time, gain and contrast in order to detect the 
fluorescence labeling. In the following experiment we therefore decided to increase the 
concentrations of the nanoprobe.  
 
It had already been observed that extended incubation times strongly affected cellular 
fluorescence intensity, and further titrations of this aspect were therefore introduced after 
elevating the nanoprobe doses; two and four hours of incubation with the nanoprobe.  
 
 
Figure 4.6: Representative overview of part of the 96-well plate layout used for the HTI experiments of 
Melmet 5 pGF1 (A) and the red image channel for H1_DL2 (B). In 4.6 A, three channels are 
superimposed on each other, Hoechst 33342 (blue), GFP (green) and Dyo-615 (red). Thick red arrows 
illustrate how the red fluorescence increased in a gradient-fashion due to increasing nanoprobe doses 
and incubation times. Images were acquired with a 10X objective. Collages were created in 
CellProfiler.  
 
Figure 4.6 shows that a gradient of increasing red fluorescence was induced with increasing 
nanoprobe doses and incubation times, as illustrated with the red arrows. Figure 4.6 B better 
visualizes the fluorescence from the red image channel due to superimposition of three 
channels in Figure 4.6 A (GFP, Hoechst 33342 and Dyo-615). All representative images 
acquired during HTI experiments were thereafter quantified to easier demonstrate cellular 
fluorescence intensities within the three cell lines studied. In the following Figures 4.7-4.9, all 
measurements at 24 hours incubation time are compared statistically using a two-tailed 
Students t-test.  
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Figure 4.7: Intensity graphs on Dyo-615 fluorescence for Melmet 1 pGF1. The numbers on the x-axis 
correspond to concentration nanoprobe given to the cells in units µg/mL. The y-axis shows the relative 
pixel intensities represented by the different samples. Abbreviations: n.s.: not significant, *: p<0,05. 
Mean ± SD, n=2. 
 
 
When comparing Melmet 1 pGF1 cells labeled with 100 and 200 μg/mL, and 200 with 300 
μg/mL for 24 hours, respectively, none of the measurements displayed significantly different 
fluorescence intensities. Cells labeled with 400 μg/mL contrast agent showed the highest 
cellular fluorescence intensity. A two-way ANOVA, in which different time points were 
compared, resulted in a p-value of 0.22.  
 
 
Figure 4.8: Intensity graphs on Dyo-615 fluorescence for Melmet 5 pGF1. The numbers on the x-axis 
correspond to concentration nanoprobe given to the cells in units µg/mL. The y-axis shows the relative 
pixel intensities represented by the different samples. Abbreviations: n.s.: not significant, *: p<0,05. 
Mean ± SD, n=2.  
 
 
Melmet 5 pGF1 cells showed significantly higher fluorescence intensity when comparing 100 
with 200 μg/mL and 300 with 400 μg/mL, but not between 200 and 300 μg/mL. The highest 
intensities were equally as for Melmet 1 pGF1 cells found for contrast agent labeling with 400 
μg/mL. Two-way ANOVA test resulted in a p-value of 0.008.  
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Figure 4.9: Intensity graphs on Dyo-615 fluorescence for H1_DL2. The numbers on the x-axis 
correspond to concentration nanoprobe given to the cells in units µg/mL. The y-axis shows the relative 
pixel intensities represented by the different samples. Abbreviations: n.s.: not significant, *: p<0,05, **: 
<0,01. Mean ± SD, n=2. 
 
H1_DL2 on the other hand, showed a larger increase with elevated nanoprobe doses than the 
other two cell lines, for which all compared measurements at 24 hours incubation time were 
statistically higher with increasing nanoprobe doses. Two-way ANOVA test resulted in a p-
value of <0.0001. Thus, to avoid loading the cells with too much contrast agent, and still 
achieve a reasonably high fluorescence signal, we chose to work further with a dose at 200 
μg/mL with an incubation period at 24 hours.  
 
4.3 Confocal imaging: Intracellular location of the nanoprobe 
To better study subcellular location of the glycogen nanoprobe after labeling, single H1 cells 
labeled with MitoTracker and Hoechst 33342 were studied by confocal microscopy.  
 
 
Figure 4.10: Confocal images of a single H1 cell. Red channel shows the Dyo-615 segment of the 
glycogen nanoprobe, the green channel MitoTracker for labeling of mitochondria and the blue channel 
Hoechst 33342 for DNA analysis. A merged image of all channels with several cross-sections is seen 
to the right. Scalebars 20 µm. 
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The micrographs showed no colocalization between Dyo-615 and MitoTracker. A 
concentrated area of signal from Dyo-615 was detected in the perinuclear region and also 
distributed in several small foci throughout cytoplasm as seen in Figure 4.10.  
 
4.4 Resazurin assay: Cell viability   
The viability of labeled cells was studied by using a resazurin-resorufin reduction assay as 
described in Chapter 3.3. All cell samples were seeded at day one, nanoprobe added after an 
incubation time of 24 hours before resazurin solution was added after the exposure times 
shown on the x-axis in all diagrams in Figures 4.11-4.13. The measurements in relative 
fluorescence units (RFU) indicate proliferating and thereby viable cells sampled four hours 
after adding resazurin to the 96-well plates with labeled cells. Unlabeled cells, “NC”, were 
statistically compared to cells labeled with a nanoprobe dose of 200 μg/mL using a two-tailed 
Students t-test.  
 
 
Figure 4.11: Cell metabolism graphs of Melmet 1 pGF1 with increasing exposure time with the 
glycogen nanoprobe in multiple 96 well plates. Abbreviations: RFU: relative fluorescence units, NC: 
negative control, ns.: not significant, **: p<0,01, ****: p<0,0001. Mean ± SD, n=6.  
 
 
Figure 4.11 demonstrates a temporal increase in Melmet 1 pGF1 proliferation as seen by the 
increasing RFU numbers. It was also seen that Melmet 1 pGF1 cells were minimally affected 
by being labeled with the nanoprobe up to 48 hours in culture. From 72 hours, labeled cells 
had a lower capacity to reduce resazurin to resorufin, which indicated decreased proliferation.  
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Figure 4.12: Cell metabolism graphs of Melmet 5 pGF1 with increasing exposure time with the 
glycogen nanoprobe in multiple 96 well plates. Abbreviations: NC: negative control, ns.: not significant; 
*: <0,05. Mean ± SD, n=6.  
 
 
Figure 4.12 indicates that the proliferation rate of labeled as well as unlabeled Melmet 5 
pGF1 cells leveled somewhat of after 72 hours in culture. At 24 hours, cells labeled with 200 
μg/mL nanoprobe showed a lower proliferation than unlabeled cells. From sampling times 48 
to 120 hours, no significant difference between the two populations was detected. 
  
 
Figure 4.13: Cell metabolism graphs of H1_DL2 with increasing exposure time with the glycogen 
nanoprobe in multiple 96 well plates. Abbreviations: NC: negative control, ns.: not significant, ****: 
p<0,0001. Mean ± SD, n=6.  
 
H1_DL2 cells showed a temporal increase in RFUs for all time points. No statistical 
difference was found between labeled and control H1_DL2 cells for timepoints prior to 120 
hours of exposure to the nanoprobe.  
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4.5 Monolayer wound healing assay: Cellular migration  
Melmet 1 pGF1 cells labeled with 200 μg/mL glycogen nanoprobe were studied and 
compared to unlabeled Melmet 1 pGF1 cells in a monolayer wound healing assay. This is 
based on the cells properties to close an induced wound, to reestablish intercellular contact.  
 
 
Figure 4.14: Representative monolayer wound healing micrographs of Melmet 1 pGF1 cells. The red 
borders around the wound illustrates wound size at 0 (A), four (B), eight (C) and 14 (D) hours after 
initiation of the experiment. Scalebar for A-D is 100 µm as seen in D. A zoomed area of the red border 
at two hours is included in E, with scalebar 50 µm. All micrographs are captured with objective 10X.  
 
 
 
Figure 4.15: Quantification of monolayer wound healing. Four representative images from each time 
point as seen on the x-axis were quantified as percent migrating Melmet 1 pGF1 cells until cell 
confluency within the wound area. Abbreviations: n.s.: not significant. Mean ± SD, n=4.  
 
Quantification as seen in Figure 4.15 was enabled using the red outlines created in FIJI and as 
shown in Figure 4.14. The resulting numbers showed that there was a tendency that labeled 
cells migrated more slowly than unlabeled cells, with no significant difference at either time 
point. Both cell samples displayed confluency 14 hours after start of the experiment.  
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4.6 Duration of cellular fluorescence: Nanoprobe clearance 
It was expected that the cultured cells exocytosed the nanoprobe gradually over time 
alongside with ongoing proliferation. Thus, the duration of fluorescent signal from the Dyo-
615 encompassed in the nanoprobe was used to study this. The cells were examined by light 
microscopy at 0, 24, 48, 72 and 96 hours after an incubation period at 24 hours with 200 
μg/mL of the glycogen nanoprobe in growth medium.  
 
 
Figure 4.16: Representative microscopy images of Melmet 1 pGF1 (A-E), Melmet 5 pGF1 (F-J) and 
H1_DL2 (K-O) up to five days after labeling the cells with the glycogen nanoprobe. 20X objective.  
 
 
Melmet 1 pGF1 cells displayed a slight increase in visual fluorescence intensity from 0 to 24 
hours (Figures 4.16 A and B), before it appeared that the fluorescence intensity leveled off 
(Figures 4.16 C-E). Melmet 5 pGF1 cells displayed the most distinct reduction in 
fluorescence intensity for all time points (Figures 4.16 F-J). H1_DL2 cells demonstrated the 
strongest signal of all cell lines initially (Figure 4.16 K). At 48 hours and onwards, a 
pronounced decrease in fluorescence intensity was noted for all three cell lines. At 96 hours, 
only fragments of the nanoprobe were left in wells with Melmet 5 pGF1 cells (Figure 4.16 J), 
whereas a subset of Melmet 1 pGF1 and H1_DL2 cells displayed fluorescence signal from 
intracellular locations (Figures 4.16 E and O).  
 
The fluorescence intensity of four representative images of each micrograph corresponding to 
Figure 4.16 were quantified in the same way as in the pilot project and presented in Figure 
4.17. 
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Figure 4.17: Temporal changes in mean cellular fluorescence intensity measured at the timepoints 
indicated on the x-axis in hours for Melmet 1 pGF1, Melmet 5 pGF1 and H1_DL2. Mean ± SD, n=64.  
 
 
The numbers seen in Figure 4.17 validate the differences between cell lines observed from the 
micrographs in Figure 4.16, as well as a temporal decline in fluorescence intensities. Also, a 
slight increase in fluroescence intensity was verified for Melmet 1 pGF1 cells from 0 to 24 
hours. At 96 hours, a mean value of cellular histogram intensity was registered at 3 for 
Melmet 5 pGF1 cells, which equaled the background noise of all fluorescence images in 
Photoshop. A two-way ANOVA analysis of the different time points gave p<0.0001.   
 
4.6.1 Cell proliferation and death    
Cell proliferation and death was monitored alongside with the imaging experiments as 
described in Chapter 3.2.6 and presented in Figures 4.18-4.20. The time points agree with 
those in the preceding Figures 4.16 and 4.17.  
 
 
Figure 4.18: Cell proliferation and death for Melmet 1 pGF1. Labeled and unlabeled cells were 
cultured in six-well plates alongside with imaging experiments, in which labeled cells were constantly 
exposed to 200 µg/mL glycogen nanoprobe in growth medium. Abbreviations: n.s.: not significant, h: 
hours. Mean ± SD, n=6.  
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For Melmet 1 pGF1 (Figure 4.18), there was a tendency that unlabeled cells proliferated 
faster than labeled from 24 to 96 hours. The number of dead cells found for the two 
populations was quite similar throughout the sampling time. None of these observations were 
statistically different when analysed with a two-tailed Students t-test.   
 
 
Figure 4.19: Cell proliferation and death for Melmet 5 pGF1. Labeled and unlabeled cells were 
cultured in six-well plates alongside with imaging experiments, in which labeled cells were constantly 
exposed to 200 µg/mL glycogen nanoprobe in growth medium. Abbreviations: n.s.: not significant, *: 
p<0,05 h: hours. Mean ± SD, n=6. 
 
 
Figure 4.19 demonstrates that Melmet 5 pGF1 proliferation is minimally affected by labeling 
the cells with glycogen nanoprobe. A significantly higher amount of dead labeled cells 
compared to unlabeled was found at 0 hours when analyzed with a two-tailed Students t-test.    
 
 
Figure 4.20: Cell proliferation and death for H1_DL2. Labeled and unlabeled cells were cultured in six-
well plates alongside with imaging experiments, in which labeled cells were constantly exposed to 200 
µg/mL glycogen nanoprobe in growth medium. Abbreviations: n.s.: not significant, h: hours. Mean ± 
SD, n=6. 
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Similarly to the Melmet 1 pGF1 cell line, there was a tendency that unlabeled cells 
proliferated more quickly as also found for the H1_DL2 cells. Also, there was a tendency that 
labeled cells displayed a higher number of dead cells than unlabeled. An increase in cell death 
was found for all three cell lines at 96 hours compared to previous time points. A high degree 
of cell confluency was at that time visually observed within all wells.   
 
4.7 Soft agar assay: Investigation of the cells in a 3D environment 
Melmet 1 pGF1, Melmet 5 pGF1 and H1_DL2 cells prelabeled with 200 μg/mL glycogen 
nanoprobe were cultured in soft agar for 14 days before they were examined for fluorescence 
using the Nikon TE2000 microscope.   
 
 
Figure 4.21: Representative images of Melmet 1 pGF1 (A), Melmet 5 pGF1 (B) and H1_DL2 (C) 
colonies. Scalebar 100 µm. Exposure time Dyo-615: 0.5 s, gain 6.8. n=4 experiments.  
 
 
The micrographs of Melmet 1 pGF1 cells revealed scattered cells, with a small degree of 
cellular spheroids. A relatively strong fluorescence signal was detected from the cytoplasm of 
some of the cells as seen in Figure 4.21 A. Melmet 5 pGF1 cells showed a larger ability to 
form cellular colonies, occuring in z-direction to a larger extent than for the other two cell 
lines (Figure 4.21 B). The fluorescence signal was also detected from these cells, especially 
the central parts of colonies. Further, the H1_DL2 cells showed smaller and more planar 
colonies than Melmet 5 pGF1, yet with strong fluorescence signal (Figure 4.21 C).  
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4.8 Bioluminescent imaging (BLI): Tumor take and development 
Tumor-take and progression was revealed by BLI two and four weeks after subcutaneous 
injection of 1·106 H1_DL2 cells into five nod/scid mice as shown in Figures 4.22 and 4.23.  
 
 
Figure 4.22: Five nod/scid mice injected with 1·106 H1_DL2 cells two weeks prior to BLI. Two mice 
received tumor cells in two locations, whereas the remaining achieved tumor cells into one location.  
 
The images in Figure 4.22 demonstrate that tumors were produced in all mice two weeks after 
injection. Based on BLI intensity measurements, the two mice that received two injection 
doses developed larger tumors than those who only received one. Tumors were estimated in 
the scale of 0.5-2.0 mm diameter.  
 
 
Figure 4.23: Five mice injected with 1·106 H1_DL2 cells four weeks earlier.  
 
 
Figure 4.23 demonstrated further growth of subcutaneous tumors in all mice. According to the 
intensity scale shown to the right of each animal, none of the tumors had developed hypoxic 
areas central in the tumors. Approximate tumor size was in the area 3.0 to 5.0 mm in 
diameter.  
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4.9 MRI 
Before the nanoprobe was tested in vivo on tumor-bearing nod/scid mice by MRI, we wanted 
to study whether the contrast agent was able to reduce the T1 relaxation times in vitro. This 
was carried out using the phantoms described in Table 4 in Chapter 3.2.3.   
 
4.9.1 In vitro MRI: Verification of nanoprobe doses from HTI experiments 
A study of changes in relaxation times was performed using the preclinical MR scanner. 
Since Gd is a T1 reducing contrast agent, only this parameter was studied, i.e. we did not focus 
on T2 relaxation. The measured T1 relaxation times for the tubes (comparing two and two 
tubes with equal numbers of labeled and unlabeled cells) were analysed using a two-tailed 
Students t-test. T1 relaxation times for phantoms with various amounts of cells are shown for 
Melmet 1 pGF1, Melmet 5 pGF1 and H1_DL2 in Figures 4.24-4.26, whereas values found for 
control phantoms are listed in Table 5.   
 
Table 5: T1 constants for control phantoms on Bruker Pharmascan 7 Tesla (T)  
Phantom Content Agar concentration T1 value 
I Agar stock solution  2 % 2 375 ± 66.9911 msec 
II Agar with ALT DMEM 1 % 2 520 ± 59.2117 msec  
III Agar with 1 mg/mL glycogen nanoprobe 1 % 1 132 ± 17.6081 msec 
IV Agar with water 1 % 2 502 ± 67.7428 msec 
V Pure water 0 % 2 720 ± 57.1421 msec 
 
 
Figure 4.24: T1 relaxation times for Melmet 1 pGF1 phantoms containing various cell concentrations 
as indicated on the x-axis. T1 values were measured in milliseconds (ms). Mean ± SD, n=1.  
 
 
The T1 times found for Melmet 1 pGF1 showed a clear reduction in phantoms with labeled 
cells for the three highest cell concentrations. The corresponding phantoms with 250 cells/μL 
demonstrate that the effect of contrast enhancement is no longer present.   
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Figure 4.25: T1 relaxation times for Melmet 5 pGF1 phantoms containing various cell concentrations 
as indicated on the x-axis. T1 values measured in ms. Mean ± SD, n=1. 
 
 
The T1 relaxation times found for phantoms with labeled Melmet 5 pGF1 cells, showed a 
smaller reduction compared to what was seen for Melmet 1 pGF1. A significant lower T1 
value was still found for the two highest cell concentrations investigated by MRI. At 750 
cells/μL and below, no significant differences between control and test phantoms were found, 
indicating that it is not possible to detect the T1 contrast agent at these concentrations.  
 
 
Figure 4.26: T1 relaxation times for phantoms with labeled and unlabeled H1_DL2 cells, at the 
concentrations shown on the x-axis. T1 values measured in ms. Mean ± SD, n=1. 
 
 
The T1 times found for H1_DL2 cells, showed the same trend as seen for Melmet 5 pGF1 
cells, in that 1 500 cells/μL was the lowest possible concentration for detecting the nanoprobe. 
At cell concentrations 750 to 25 cells/μL, no significant difference was found.  
 
In general, a quite stable T1 value was detected for negative control phantoms with a mean 
value at 2 515.57 ms.  
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4.9.2 Pilot in vivo experiment 
Tumor uptake of contrast agent in a nod/scid mouse was studied by MRI after administration 
of the nanoprobe and Omniscan in corresponding amounts of Gd, as commonly used in the 
clinic. The results are seen in Figures 4.27 and 4.28.  
 
 
Figure 4.27: T1 weighted MRI images before (left) and after (middle and right) administration of 
glycogen nanoprobe. Abbreviations: CA: contrast agent, TR: repetition time, TE: echo time.  
 
 
An axial slice positioned approximately at the illustration to the left in Figure 4.27 
demonstrate little nanoprobe uptake into the tumor (red arrow) regardless of repetition time 
(TR). It appears that a vessel is better visualized post contrast agent administration at anterior 
segments of the tumor. The blue arrow illustrates the position of abdominal aorta and vena 
cava within close proximity, in which bright contrast is detected. Signal from vessels within 
muscle tissue are brighter post contrast agent administration (green arrow).  
 
 
Figure 4.28: T1 weighted MRI images before (left) and after (middle and right) administration of 
Omniscan. Abbreviations: CA: contrast agent, TR: repetition time, TE: echo time.  
 
The same nod/scid mouse was 24 hours later examined for contrast agent uptake in the same 
tumor using Omniscan. From Figure 4.28 it is apparent that the contrast agent was loaded into 
the tumor (red arrow) as well as intestines (yellow arrow) and vessels within muscle tissue 
(green arrow).  
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To quantify and compare the signal intensities, ROIs were created and placed at the contours 
of the tumor seen in Figures 4.27 and 4.28 and the pixel intensity was found using Photoshop 
CS5. The results are presented in Figure 4.29.  
 
 
 
Figure 4.29: T1 intensity measurements of the flank tumor in T1 weighted images before and after 
contrast agent administration at repetition times (TR) 600 and 1 000/1 200 ms, as indicated in the 
legend. Abbreviations: CA: contrast agent, ms: millisecond, TR: repetition time.  
 
 
A larger increase in T1 image brightness linked to tumor uptake of contrast agent was seen for 
the flank lesion scanned after Omniscan administration. A smaller increase in image 
brightness is seen for the tumor scanned after administering the nanoprobe.  
 
4.10 Histology 
Heamotoxylin and eosin (H&E) stained histological samples of the flank tumor showed 
central areas of hypoxia within the tumor with mitotic activity and pleomorphic nuclei. 
Prominent nucleolus and angiogenesis was also seen (data not shown).  
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5. Discussion 
 
In general, 20-40 % of all cancer patients develop brain metastases during the progression of 
malignancy, of which a fifth are diagnosed with secondary brain tumors before the primary 
site neoplasm is located or identified (85). To diagnose brain metastases, varying imaging 
modalities are used, and these are in general divided into modalities that give information on 
anatomy and pathology such as MRI, and modalities that produce functional information, 
such as the metabolism-driven image contrast acquired in nuclear medicine approaches (86). 
The respective modalities have varying strengths and weaknesses as briefly discussed in 
Chapter 1. MRI is often the modality of choice to detect CNS lesions due to the high spatial 
resolution and great soft-tissue contrast. It can still be problematic to detect tumors smaller 
than 10 mm on MRI (87), which also arises an additional challenge in melanoma patients, as 
they often develop multiple, small brain metastases (21). Multimodal imaging has emerged as 
a potent tool for improved detection (88), as this allows signal-reading from one common 
probe using more than one modality (63).  
 
Recently, increased awareness has been given to the establishment of new nanomaterials for 
cancer therapeutic, diagnostic or combined purposes (62). The nanomedicine research has 
become a multi-billion industry, in which the search for new materials and applications 
constantly continues. Nanomaterials can be used to improve the detection of metastatic 
disease to the brain, and especially in the multimodal and theranostic settings, suitable probes 
of nano-scale sizes are needed (74). By combining the emerging potential of multimodal 
imaging with a promising or well-established therapeutic agent, improved treatment outcome 
for cancer patients might be a possible impact of such theranostic entities.  
 
In this project a variety of in vitro experiments were performed to study the usability of a 
novel multimodal glycogen nanoprobe developed by Filippov and colleagues (63), on three 
metastatic melanoma cell lines. Before it is possible to study the theranostic potential of the 
nanoprobe in an in vivo model system, it was regarded imperative to address several 
fundamental aspects as discussed below and as described in the aims of this thesis. Multiple 
fluorescence microscopy experiments were thus emphasized, as this is a sensitive and 
functional way to study such features (89). Further, this provided robust data on cellular 
internalization of the nanoprobe demonstrated for more than one cell line and validated 
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several times in different experiments. Any applications of this particular nanoprobe on 
cancer cell lines have not been described in the literature yet, and the following discussion 
will thus form a basis for further research on the multimodal glycogen nanoprobe holding a 
prospective implementation in theranostic research.  
 
5.1 Cellular fluorescence experiments 
The initial experiments to study cellular fluorescence intensities were enabled through the 
Dyo-615 segment of the multimodal nanoprobe. The pilot project demonstrated increased 
fluorescence intensities as a consequence of elevated doses and incubation times (Figures 4.1-
4.3). In general, cellular uptake of macromolecules is presumed to occur through a 
combination of several possible mechanisms: Energy-dependent endocytosis can occur 
mediated by cavaeola vesicles, clathrin vesicles, by phagocytosis or pinocytosis, whereas 
passive uptake can occur by diffusion (90-92). Non-specific uptake means that the cell does 
not actively request the compound to be internalized, however extraneous material is still 
taken up by the cell. This usually occurs by pinocytosis for eukaryotic cells (93). To study the 
exact mechanisms responsible for cellular internalization, other methods besides light 
microscopy with or without visualization of fluorescence are usually better suited (90). Taken 
into account the size of the considered nanoprobe, 54.4 nm, some characteristics of 
internalization mechanisms can still be discussed. Several papers report that nanomaterial size 
is one of the most important predictors of cellular internalization (93-96). Meng and 
colleagues reported that a nanoparticle with a diameter at 110 nm was internalized into HeLa 
cells and a lung cancer cell line through macropinocytosis, which was determined due to the 
presence of large cytoplasmic vesicles (97). Further, Yoo and colleagues describe that 
particles at a size of 60 nm entered a cell line derived from liver cancer through a combination 
of passive diffusion and non-specific endocytosis (98). Internalization of particles below a 
size of 30 nm is usually less dependent on particle size and a combination of several factors 
such as particle morpholology, charge and the cell type studied is more decisive with respect 
to internalization mechanism (90). Thus, it can be indicated that the size of the glycogen 
nanoprobe is within the limit of what might involve passive diffusion and non-specific 
endocytosis. This is in accordance with Glaumann and colleagues who performed in vivo 
experiments on rats. In their studies, glycogen labeled with isotopes was injected 
intravenously, before cellular internalization was studied by electron microscopy. Their 
findings also suggested non-specific endocytosis (99). On the other hand, Rejman and 
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colleagues demonstrated cellular uptake of microspheres at 50 nm into a melanoma cell line 
to occur through clathrin-mediated pathways (100). Thus, additional studies are needed to 
specifically investigate the exact internalization mechanism of the glycogen nanoprobe taken 
into account other aspects such as the charge of the probe. Nevertheless, the pilot project 
demonstrated that the probe was internalized into all three cell lines investigated, which was 
essential for further experiments with the glycogen nanoprobe.  
 
From the pilot project we observed cellular fluorescence signal dispersed throughout 
cytoplasm, and that larger portions of the cells were stained the higher the nanoprobe doses 
used. When single H1 cells were investigated with confocal microscopy, signal from Dyo-615 
was observed concentrated in the perinuclear region and scattered throughout the cell in focal 
areas of varying sizes (Figure 4.10). No colocalization with labeled mitochondria was 
detected, which excludes accumulation into this organelle. Although no fluorescent markers 
for these sites were used, the images might indicate that the probe was accumulated in Golgi 
apparatus or endoplasmic reticulum (ER) and vesicles of varying sizes. Seen in context with 
Glaumanns and Rejmans research (99, 100) as mentioned above, we have reason to assume 
that these vesicles are endosomes or matured lysosomes. Different degradation enzymes are 
abundantly present in lysosomes for breakdown of several biomolecules such as glycogen. 
This organelle varies in size dependent on activity (101), which was also observed in our 
confocal experiments. Nanomaterial concentration within these sites is also in consistence 
with Kelf and colleagues research (93). This can be studied by using customized organelle 
dyes and subsequent analysis for any colocalization with Dyo-615 by confocal microscopy. 
Glycogen was found within lysosomes by Glaumann up to 24 hours after administration, 
before the end products escaped back into the cytoplasma (99). Possible subsequent 
employment of degraded glycogen might be glycolysis, pentose phosphate pathway or 
production of glucose, which occurs in the cytoplasm and is often not associated with any 
organelle-specific site (102, 103).  
 
A labeling efficacy at 100 % was found for 24 hours of incubation, whereas a relatively high 
efficacy was found for six hours of incubation as well (Figure 4.5). Rejman and colleagues 
also studied cellular internalization efficacy of microspheres of higher diameters; 100, 200, 
500 and 1000 nm (100). By confocal microscopy and fluorescence-activated cell sorting 
(FACS), they demonstrated that all types of particles below a diameter of 500 nm were 
efficiently internalized under normal incubation conditions, and that particles above this size 
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were not coherently internalized. Further, they reported a reduced efficacy in uptake with 
increasing microsphere size, and particles around 50 nm displayed the optimal size for 
cellular internalization (100), which also is reported by others (93, 95). These findings are 
promising for the glycogen nanoprobe, and can be seen in line with our observations from 
fluorescence microscopy.  
 
When comparing unlabeled cell samples with cells labeled with varying doses of the 
nanoprobe in Figures 4.1-4.3, no distinct morphological or behavioral alterations were 
observed. Single Melmet 1 pGF1 cells appeared as more independent than the other two cell 
lines, and a broad lamellipodium was noted for both labeled and unlabeled cells. Melmet 5 
pGF1 cells displayed a star-like morphology with demarked filopodia in bright field 
micrographs both when labeled, and when used as negative controls. The growth pattern of 
this cell line occurred in patches, for labeled as well as unlabeled cells. H1_DL2 cells 
demonstrated elongated filopodia, similarly as what was seen for the Melmet 5 pGF1 cells. 
The relatively low proliferation rate for H1_DL2 cells compared to the other two cell lines 
remained the same for labeled as well as unlabeled cells. Multinucleated cells were 
occasionally observed for Melmet 5 pGF1 and H1_DL2, both for labeled and unlabeled cells. 
According to Weihua and colleagues, such larger, multinucleated cells are commonly found 
in established tumor cell lines (104). They often result from lack of cytokinesis following 
mitosis and provide an example of an irregular cancer cell phenotype associated with 
malignancy. The morphology and behavior of cultured cells thus remained the same for both 
labeled and unlabeled samples, indicating adequate short-term cell viability in vitro.   
 
Based on HTI experiments (Figures 4.6-4.9) and the cell viability after labeling with varying 
amounts of the glycogen nanoprobe (Figure 4.11-4.13 and 4.18-4.20), a dose of 200 μg/mL 
was chosen with incubation time 24 hours. As stated in Chapter 4.2, the nanoprobe doses 
were increased in HTI experiments from those used in the pilot project due to the low 
fluorescence intensity, as we had to use high gain and exposure time for detection. When 
bearing in mind that 100 μg/mL as used in the pilot project was considered a too low dose, 
this was used for comparison of higher doses (200-400 μg/mL) in HTI.  
 
With respect to incubation time, we established already in the pilot project that increased 
incubation times with the nanoprobe had major impact on cellular fluorescence intensity. To 
investigate this while using higher nanoprobe doses in the HTI experiment, we chose to 
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include further titrations of this with two and four hours as well. As expected, we did not 
obtain an adequate fluorescence signal, which further suggests that longer incubation times 
are advantageous. From Figure 4.11 we observed a decreased viability for Melmet 1 pGF1 
cells incubated with the nanoprobe more than 48 hours, which indicated that incubation times 
longer than this were unfavourable. Despite the fact that Melmet 5 pGF1 cells displayed 
decreased viability after 24 hours of incubation with the nanoprobe (Figure 4.12), this was 
only to a small degree emphasized, as subsequent measurements contradicted this. Thus, as 
all fluorescence intensity measurements after 24 hours of incubation with the nanoprobe were 
considerable higher than two to six hours as seen in Figures 4.7-4.9, we concluded that this 
was sufficient and that healthy cell samples were maintained.  
 
Regarding nanoprobe dose, it was noted that for two of the three cell lines studied, i.e. 
Melmet 1 pGF1 and Melmet 5 pGF1, increasing the dose from 200 μg/mL to 300 μg/mL did 
not result in a significant increase in fluorescence signal as seen in Figures 4.7 and 4.8. It is 
relatively accessible to manipulate the microscope settings to improve fluorescent contrast by 
adjusting exposure parameters such as gain and exposure time. On MRI on the other hand, 
there are less opportunities to adjust T1 weighted image sequences to improve the T1 effects. 
However, it is known from the publication by Filippov that the wt% of Gd is higher than that 
of Dyo-615 in the probe, at 3.19 and 0.33, respectively (63). This indicates that it should be 
easier to obtain contrast agent-effects on MRI compared to fluorescence microscopy using the 
same dose. Also, we endeavored not to overload the cells with too large amounts of the 
nanoprobe, exemplified by 400 μg/mL, as we considered lower doses less harmful. With this 
in mind, it was not regarded necessary to increase the nanoprobe dose beyond 200 μg/mL, 
thus a dose at 200 μg/mL for 24 hours thus seemed appropriate for in vitro samples for both 
modalities.  
 
All three cell lines used during the project displayed a clear fluorescence signal after labeling. 
Still, some individual variations were observed through the pilot project (Figures 4.1-4.3), 
HTI experiments (Figures 4.7-4.9) and assessments of fluorescence duration after labeling 
(Figures 4.16-4.17). Although the fluorescence measurements from the HTI experiments are 
not directly comparable to measurements on micrographs captured with the Nikon TE2000 
microscope, a common intercellular pattern was observed: Predominantly, H1_DL2 cells 
displayed the highest signal, Melmet 5 pGF1 in between and Melmet 1 pGF1 the lowest 
signal. This pattern, which was found through manual fluorescence measurements in the pilot 
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project, and through an automatic processing pipeline in CellProfiler, suggests reliable 
cellular fluorescence data, independent on the approach used. Rima and colleagues 
demonstrated diverse degrees of cellular internalization efficacy of a Gd-based nanoparticle 
into a larynx cancer cell line, a glioblastoma cell line and healthy T lymphocytes (90). This 
was attributed to varying membrane permeability for the individual cell lines. Further, 
Wilhelm and colleagues reported on varying internalization capacities of different cell lines, 
which affected the total cellular uptake (105). These aspects were not studied in detail within 
this project, however the tendencies between the different cell lines seen in our fluorescence 
experiments might be due to individual variations in permeability properties and ability for 
internalization, as the Melmet 1 pGF1 cell line exhibited a lower permeability and/or potential 
than the other two cell lines. Nevertheless, as individual cell lines have different properties as 
described above, such variations should to a certain degree be expected. The magnitude of 
this aspect was not considerable high and thus not emphasized any further.  
 
After determining the appropriate labeling dose, the cell lines were individually studied with 
fluorescence microscopy to investigate nanoprobe clearance. Nanomaterial clearance is 
according to Naahidi and colleagues determined by a combination of size, hydrophobicity and 
electrical charge of the probe (94). We observed a gradual decrease in fluorescent signal in 
our experiments over five days (Figures 4.16-4.17). It was observed that the proliferation 
rates shown in Figures 4.18-4.20 could be correlated to the fluorescent signal. The H1_DL2 
cells proliferated slower than the other two cell lines. This particular cell line also displayed 
the highest fluorescence signal. Melmet 5 pGF1 on the other hand, which has the highest 
proliferation rate, showed a relatively quick drop in fluorescence intensity after the first 
imaging (Figure 4.16 G). Ambrozek-Latecka and colleagues described how appropriate 
fluorescent assays can realistically indicate cell proliferation in culture, as the signal was 
reduced with increased cell division (106). Also, it should be stated that our experiment was 
not specifically customized to capture proliferating cells in culture. Ambrozek-Lateckas 
findings are partly in accordance with our findings, however there was an exception to this 
association for Melmet 1 pGF1 cells: From the first to the second time point, Melmet 1 pGF1 
cells demonstrated an increase in cellular fluorescence intensity (Figures 4.16 B and 4.17). 
This could perhaps be due to a slower uptake, possibly as a consequence of the inferior cell 
membrane permeability or internalization capacity as discussed above. Further, it could result 
from an artefact within the experiment. As seen after 96 hours, Melmet 5 pGF1 cells showed 
a more or less complete clearance of fluorescence signal (Figure 4.16 J), whereas remaining 
 52 
signal was detected in Melmet 1 pGF1 and H1_DL2 samples (Figure 4.16 E and O). Thus, a 
complete clearance would likely have been observed in these two cell lines by increasing the 
time aspect for the particular study. This is regarded a favorable feature of nanomaterials after 
the introduction into the body and completion of its intended purpose and performance (94).  
 
The micrographs acquired of metastatic melanoma cells cultured in 3D, showed the presence 
of fluorescence signal within central areas of cellular clusters or colonies after 14 days in soft 
agar culture (Figure 4.21). Under these conditions, several micro-environmental factors 
changed as described in Chapter 1.3.1. Because the altered growth environment contributes to 
a spatially impeded cell spreading and proliferation as reported by Baker and colleagues, 
many cellular processes, such as proliferation, are substantially decelerated in 3D cultures. 
Cells in such environments are thus forced to mediate or cleave the physical scaffold they are 
situated in (48). Consequently, the prolonged fluorescence duration discovered in this assay is 
in accordance with this. The micrographs of Melmet 5 pGF1 and H1_DL2 cells demonstrated 
colonies rather than clusters, as seen for Melmet 1 pGF1. This suggested that Melmet 5 pGF1 
and H1_DL2 proliferation had occurred and aggregated on the outside of colonies due to the 
observation of central areas of fluorescence signal. In general, it was a challenge to acquire 
adequate in-focus micrographs because cells in 3D cultures form ellipsoid morphologies, in 
the scale of 10 to 30 μm (107), as opposed to a few μm when cells are cultured in monolayer 
(108). Thus, on the microscope the exposure time was shortened and the gain increased to 
facilitate the acquisition of the fluorescence. Melmet 5 pGF1 was in particular difficult to 
image, as these cells to a larger extent migrated and proliferated in all three dimensions 
compared to Melmet 1 pGF1 and H1_DL2 cells. Pampaloni and colleagues acquired the 
micrographs of such cellular spheroids using stack methods in light, electron and multiphoton 
microscopy, which can be considered a better method than ours (107). Bilgin and colleagues 
describe a curvature-based partitioning image processing pipeline with segmentation and 
subsequent profiling to quantify cells in 3D culture. The purpose of their description was to 
study biomarkers, potential therapeutic targets and atypical signaling pathways (108). Our 
goal was only to examine the presence of fluorescent signal after an elevated period of 
prelabeled cells in 3D culture, for which reason no further analysis was done. The fact that 
fluorescence signal was observed within some cells of all three cell lines after 14 days in 3D 
culture is promising for further in vivo use of the nanoprobe. It is known that not all cancer 
cell lines have the ability to form colonies or spheroids when grown in 3D cultures (109). 
Prasmickaite and colleagues reported on the formation of spheroids as well as colonies for 
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Melmet 1 and Melmet 5 cells (82), which is in disagreement with our findings. Our 
experiment was repeated three times, which should suggest that our observations are reliable. 
On the other hand, the culture conditions differed, as Prasmickaite provided their cells with 
specialized stem cell growth conditions (82). Also, the disagreement can be a result of the 
different terms used to describe cell growth in 3D cultures, such as spheroids, colonies, 
aggregates and clusters (49, 109-111), as no clear or consistent definitions were found in 
different papers. It is however important to study cellular behavior by using a multi-layered 
agar gel approach of intermediate complexity, as a next step from monolayer culture. Several 
therapeutic agents or probes have previously lost their potential when researchers have 
transferred them from monolayer to 3D cell cultures. Thus, it is possible to avoid the overuse 
of animal models exclusively based on results from monolayer (112).   
 
5.2 Cell viability  
We have previously shown linearity between fluorescence signal and cell proliferation when 
using the resazurin assay with signal detection after four hours (unpublished data). The 
proliferation of Melmet 5 pGF1 and H1_DL2 cells was minimally affected by labeling the 
cells with 200 μg/mL of the nanoprobe as seen by the resazurin assay (Figures 4.12 and 4.13), 
however with two exceptions: The first exception is Melmet 5 pGF1 cells incubated with 200 
μg/mL glycogen nanoprobe for 24 hours prior to resazurin measurements, in which lower 
numbers were found compared to negative control cells. This indicated reduced cell viability 
at this particular read-out. When seen in correlation with the proliferation study in Chapter 
4.6.1, there is a consistency with the number of dead Melmet 5 pGF1 cells found at time point 
0, which is the corresponding time. However successive measurements contradict with this, as 
this trend leveled off after elevated incubation times with the nanoprobe. Further, as seen 
from Figure 4.13, labeled H1_DL2 cells did in general transform an equal amount of 
resazurin as seen for negative control samples, until 120 hours of incubation. The 
proliferation study did not extend over that time period for comparison, however the resazurin 
measurements indicated cytotoxic effects or reduced cell proliferation at this time.  
 
Melmet 1 pGF1 cells, showed a reduced capacity to transform resazurin to resorufin after 
being exposed to the nanoprobe for 72 to 120 hours (Figure 4.11). It seemed that all 
nanoprobe doses above 200 μg/mL impaired cell proliferation for this particular cell line. The 
same tendency can also be seen from the proliferation study (Figure 4.18), as labeled cells 
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tended to proliferate less than unlabeled.  
 
According to Filippov and colleagues, any cells incubated with the glycogen nanoprobe are 
likely to treat the added glycogen as their own (63). Thus, it seemed that Melmet 1 pGF1 cells 
did not tolerate this as well as the other two cell lines at elevated incubation times in 
monolayer in vitro. All cells were checked well by well at each time point to confirm the 
presence of live cells. The reduced RFUs detected for the cell lines at varying incubation 
times were thus not necessarily a result from visually observed cell death, but can likely be 
due to decreased cell proliferation. The magnitude of cytotoxic effects of Gd chelates is 
debated (113, 114), but can be a contributing factor to cell viability. This aspect was not 
studied further within this project.  
 
When comparing the numbers obtained during resazurin experiments with the proliferation 
study, our findings suggest that the former is more sensitive. Although counting cells is a very 
direct way to monitor cell proliferation, the estimates are based on small extractions of cell 
solution from an in comparison large volume with cells. The measurements of fluorescence 
units in the resazurin assay is in contrast based on individual cells contribution to a total 
number in relative entities. In conclusion, adequate short-term cell viability after labeling with 
200 μg/mL of the nanoprobe was found for all cell lines. 
 
5.3 Cellular migration  
Due to technical problems with the imaging equipment used to capture cellular wound healing 
in monolayer, data was only acquired on one of the three cell lines used throughout this 
project, namely Melmet 1 pGF1. As demonstrated in Figure 4.15, there was a tendency that 
labeled cells migrated more slowly than unlabeled cells, however this was not statistically 
significant. This is in line with other studies, showing no or minimal effect after cell labeling 
(21). Monolayer migration studies have previously demonstrated to be quite useful, as these 
to some extent mimic a real in vivo situation as described by Haudenschild and colleagues 
(115). 
 
Preliminary migration data, which included all three cell lines (data not shown), demonstrated 
that the wound was closed for all samples after 60 hours. This is also in consistence with 
Liangs wound healing protocol (116). For Melmet 1 pGF1 on the other hand, the wound was 
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healed already 14 hours after start of the experiment. According to Nygaard and colleagues 
(117), the considered cell line is despite lower proliferation rate than Melmet 5, a highly 
invasive cell line due to expression of a genetic signature associated with an invasive 
phenotype (117). The same authors have found genetic signatures in Melmet 5 cells that are 
in accordance with a more aggressive proliferation pattern, but lack the invasiveness detected 
for Melmet 1 cells. This explains the rapid migration detected for Melmet 1 pGF1 cells.  
 
5.4 MRI experiments  
Gd has several unpaired electrons and is, when chelated, characterized as a paramagnetic 
contrast agent. Major magnetic moments are consequently produced through reduced T1 
relaxation constants in areas of contrast agent enhancement as illustrated in Figure 1.6 A. T2 
relaxation is also reduced, however, only to some extent and it is an accepted certainty that 
Gd is an established T1 agent. Thus, it was of interest to study T1 relaxation to demonstrate 
whether the nanoprobe had functionality in MRI, and consequently T2 measurements were 
neglected. The motivation for measuring relaxation constants is that this is a more reliable 
marker for tissue properties compared to signal intensities based on MR images (118). A 
point of reference is homogenous image contents and high spatial resolution. This was 
attempted by providing evenly dispersed cells in phantoms and by using T2-weighted images 
to select a superior axial slice to map, i.e. without air pockets.  
 
A search for more suitable materials for T1 MRI phantoms in addition to or as a supplement to 
agar seems to be the concern in several research articles (71, 73, 119, 120). According to 
Yoshimura and colleagues, our agar concentration at 2 % is within the range that mimics 
biological relaxation times (73). As stated by Hellerbach, this corresponds to a T1 value at 2 
214.27 (±23.93) ms, which they argue cannot be obtained using pure agar nor agarose 
phantoms (71). Our T1 measurements of phantom I (Table 5, Chapter 4.9.1) was somewhat 
higher than the value recommended by Hellerbach. When linking these numbers to measured 
relaxation times for phantom IV and V, we can conclude that it might have been 
advantageous to achieve lower T1 constants. This can in theory be accomplished by increasing 
the concentration of agar in the stock solution, as less water will result in shorter T1 times. 
Nevertheless, we concluded that the T1 value of phantom I was at an acceptable level to 
perform T1 relaxation experiments with nanoprobe labeled cells (2 375 ± 66.99 ms). Tissue 
relaxation constants are, however, influenced by additional and intricate factors. As described 
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by Petrén-Mallmin and colleagues, the performance of the scanner and the choice of image 
acquisition sequence can result in varying relaxation constants, which were as far as possible 
kept constant during our experiments. Also, for most tissue types, T1 constants increase with 
elevated temperatures (121). Consequently, if the temperature is altered by only one degree 
Celsius, relaxation times can be detected with an error at 1-3 % (122). The phantoms were 
therefore kept at room temperature for 30 minutes before scanning, in order to stabilize the 
temperature of the phantoms to room temperature (∼20° C).  
 
Control phantom IV and II displayed quite similar relaxation properties, with similar T1 
values as reported by Rooney and colleagues, measuring T1 values in blood (2 587 ±283 ms) 
(123). Phantom III was used to demonstrate T1 effects after adding the glycogen nanoprobe to 
agar. As the T1 value of this phantom was measured to be 55 % lower than negative control 
phantoms with unlabeled cells, T1 reductions could also be expected from labeled cells 
embedded into the phantoms. Our mean T1 value for phantoms with unlabeled cells was 2 
515.57 ms, i.e. a bit lower than phantom II, and higher than phantom I. This indicates that 
cells in phantoms slightly increase the T1 values, with small variations between different cell 
concentrations (Figures 4.24-4.26).  
 
During in vitro MRI scanning of the agar-casted cells described in Table 4, a significantly 
lower T1 relaxation value was found for labeled cells down to a cell concentration at 750 
cells/μL for Melmet 1 pGF1 (Figure 4.24) and 1 500 cells/μL for Melmet 5 pGF1 (Figure 
4.25) and H1_DL2 (Figure 4.26). Because of the opposite effect detected for 250 cells/μL for 
Melmet 1 pGF1, any reduced T1 values for lower cell concentrations cannot be ascribed to 
effects of the nanoprobe. The same was seen for Melmet 5 pGF1 and H1_DL2 at cell 
concentrations lower than 750 cells/μL. Each phantom was only scanned once, and it can be 
argued that variations in agar homogeneity, cell numbers or variations in the homogeneity of 
the magnetic field could be at least partly responsible for the varying T1 times detected for the 
lower cell concentrations. Thus, by repeating the scans on additional phantoms with the same 
cell concentrations, the T1 values for these phantoms would most likely have leveled out. This 
was not performed due to time limitations.  
 
According to Terreno and colleagues (124), cells labeled with Gd through pinocytosis, can be 
detected in MRI phantoms containing ≥5 000 cells/μL. These cells were labeled with 0–5·1010 
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Gd chelates per cell. Our findings suggests a more efficient cell labeling, as the T1 effects 
were observed down to 1 500 cells/μL for all three cell lines investigated. It should be noted 
however, that we have not studied intracellular amounts of Gd. Terreno and colleagues 
explained their observed low sensitivity to quenching due to the presence of very high 
amounts of intracellular Gd. Another study previously performed in our research group on a 
T2* agent in MRI phantoms, showed efficient contrast agent detections down to cell 
concentrations at 250/μL, which was further validated by in vivo experiments (125), 
indicating a higher sensitivity than found for the glycogen nanoprobe. This is also in 
accordance with the literature on T1 and T2* contrast agent sensitivity (126, 127).   
 
When comparing the individual T1 reductions between the different cell lines that we used, it 
is noted that Melmet 1 pGF1, which displayed the lowest fluorescence intensities when 
examined by microscopy, showed the highest T1 changes by MRI. This is opposite to what we 
expected, as the labeling method was the same for both fluorescence microscopy and MRI. 
The reason for this variation remains uncertain, however plausible explanations can be altered 
temperature or pH of the phantom content (71).  
 
A main goal was to obtain data to support the use of the nanoprobe as a tool to detect and 
possibly treat challenging malignancies, such as multiple brain metastases. As part of a «proof 
of principle», an in vivo pilot project was performed, where a mouse with subcutaneous 
tumors was scanned by MRI six weeks after injection of tumor cells. BLI was used to study 
tumor development and progression two and four weeks after subcutaneous injection of tumor 
cells, respectively. Central areas of necrosis were not observed within the tumors by BLI. 
However, the histology contradicts with this, as angiogenesis and areas of necrosis were 
found within the tumors. Thus, uptake of the nanoprobe should have occured to a larger 
extent in the tumor as well as intestines and muscle tissues as seen in Figure 4.28 for the 
animal scanned after injection of Omniscan. As T1 is reduced as a consequence of the use of 
Gd, T1 weighted images appear brighter in tissues with contrast enhancement. Therefore, the 
pixel intensity measurements of tumor tissue demonstrated in Figure 4.29 should to some 
extent predict effects of Gd, however not as accurately as relaxation mapping of T1, similar to 
what was done for in vitro MRI. The use of Omniscan resulted in a larger increase in signal 
intensity after contrast agent administration, than when using the glycogen nanoprobe.  
 
The low T1 changes induced by the nanoprobe is likely due to lower amounts of Gd in the 
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concentrations prepared of the nanoprobe, compared to Omniscan. We used the molecular 
weight of the lanthanide Gd, 157.25 g/mol to calculate the amount of nanoprobe needed to 
match Omniscan. The active contrast enhancement agent in Omniscan is gadodiamide, which 
has a molecular weight at 591.672 g/mol (128), i.e. higher amounts of the nanoprobe are 
needed to achieve corresponding T1 contrast enhancement. Thus similar contrast enhancement 
as for Omniscan could likely be achieved by using approximately four times the 
concentrations of the nanoprobe. We did not have time to pursue these experiments.  
 
As the nanoprobe dose administered to the animals was based on the amounts of Omniscan 
normally used in the clinic, it was of no concern whether the dose of Gd would be lethal to 
the animals (LD50 = 6-20 mmol/kg). On the other hand, the amount of glycogen administered 
intravenously was evaluated. According to Glaumann and colleagues research, glycogen 
injected by this administration route is lethal above 128 mg per 100 g rat (99). The animal 
studied by MRI during this experiment was given 7.85 mg per 100 g weight, which is far 
below this threshold. This indicates that the glycogen nanoprobe is safe for in vivo use, further 
underpinned by Filippovs in vivo observations of Gds temporal distribution in mice (63). 
Further, it has been argued that biodegradable probes are preferable (98), of which the 
considered nanoprobe is an example of. In general it is advised against the use of non-
biodegradable nanomaterials, as the accumulations of these materials seen in the liver or 
spleen might result in toxic effects (94). However, we did not study possible long-term side 
effects in the tumor-bearing nod/scid mice after injecting the nanoprobe. This matter was not 
addressed by Filippov either (63), and should therefore be studied in further experiments. 
 
Compared to our results on cellular internalization in vitro, the internalization of nanoprobe in 
tumor tissue (into the tumor cells as well as into the tumor matrix) is more complex in an in 
vivo setting. As glycogen is relatively inactive to amylases, it can be expected that the 
nanoprobe should survive transportation in the blood stream, and not be directly eliminated as 
its molecular weight is above renal threshold (63). The nanoprobe thus takes advantage of 
accumulation in cancerous tissue as the associated blood vessels often are dilated, leaky, 
defective, have an irregular shape and have wide fenestra due to poorly aligned endothelial 
cells, a manifestation of the EPR effect (129). Because perivascular cells, basement 
membrane and smooth muscle layer often is absent, it is subsequently possible that the 
nanoprobe can internalize into cells once located within the tumor vasculature, or it might 
diffuse from vasculature and endure in the extravascular extracellular space for several 
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minutes to hours, as effective drainage is absent. However, cellular internalization in vivo is 
further complicated due to the presence of a higher interstitial fluid pressure inside tumors 
(130). Thus, the efficient cellular uptake demonstrated for in vitro experiments is not directly 
comparable to an in vivo situation.  
 
Normally, Gd-based agents are used as extracellular contrast enhancers, and do not cross cell 
membranes (122). Recently, it has been reported on the development of Gd nanomaterials for 
intracellular use (90, 113, 127, 131, 132). If successful, such as reported by Di Corato and 
colleagues, this can give Gd-based nanomaterials potential as a cellular label for tracking by 
MRI (132). Unfortunately we were only able to obtain very preliminary data on in vivo use of 
the glycogen nanoprobe. Seen in light with the findings from in vitro MRI studies, it is 
doubtful that we can obtain a very sensitive visualization of single cells by high resolution 
MRI. The dose of the nanoprobe should still be optimized and studied further, as the cells to a 
small degree were affected by the labeling, which indicates non-toxic effects. Thus, it should 
to a higher extent be possible to follow the biodistribution of the nanoprobe and potential 
therapeutic agents in vivo.   
 
5.5 Concluding remarks 
Based on the preceding, fundamental in vitro data on the use of the novel glycogen nanoprobe 
is reported in this thesis. Through fluorescence microscopy, a high cellular internalization 
efficacy was demonstrated with an optimal labeling period at 24 hours. A dose at 200 μg/mL 
was chosen for verification experiments of the two contrast agents encompassed in the 
nanoprobe, in which MRI phantoms with labeled cells were scanned.  
 
The viability experiment based on cellular metabolism did in general demonstrate minor 
changes between labeled and unlabeled cells, which is promising in that the nanoprobe can be 
used in vivo. The experiments on nanoprobe clearance were promising with respect to the 
EPR effect proposed to occur after administering the nanoprobe into nod/scid mice in vivo, as 
any injected material should be eliminated when its intended use is performed. The results 
from 3D cell cultures also contributed to promising results with respect to in vivo experiments 
as a next step.  
 
The in vitro MRI experiments revealed a lower sensitivity of contrast agent detection than 
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microscopy experiments. Nevertheless, labeled cell concentrations down to 1 500/μL was 
detected by T1 mapping. When the nanoprobe was injected into nod/scid mice, a weak but 
existing effect of the T1 agent was observed. Further work should thus be done to optimize the 
in vivo doses due to the good findings reported on in vitro cell viability and cellular contrast 
agent uptake.  
 
Although we only performed experiments on metastatic melanoma cell lines, our experiments 
showed differences in cellular morphology and general behavior. This suggests that the 
nanoprobe can be tested for yet other cell lines derived from other tumor tissues. The novel 
glycogen nanoprobe can thus be concluded as effective for in vitro use on metastatic 
melanoma cell lines, and shows great promise to be studied further as a theranostic unit.  
 
5.6 Future perspectives  
Several of the experiments should be repeated or supplemented to delineate in detail the 
effects of labeling with the glycogen nanoprobe. The fact that data on only one cell line was 
acquired during the migration assay, is a potential drawback as this experiment was used to 
predict altered cellular migration as a consequence of labeling with the nanoprobe. We are 
currently planning to repeat this experiment including all three cell lines. This can can be 
important for the usability of the nanoprobe, as in vitro monolayer wound healing assays to 
some extent mimics a real in vivo situation. Further, additional MRI phantoms with labeled 
cells should be prepared using the same method and scanned to obtain more robust data on 
this experiment.    
 
We are currently testing further organelle markers to determine the subcellular localization of 
the nanoprobe. The results were not ready to be inclded in this thesis. Markers tested were 
ER, Golgi apparatus, lysosomes, plasma membrane and endosomes.  
 
The nanoprobe should also be tested on other cancer cell lines in vitro besides metastatic 
melanoma to study whether the results are similar. We are also planning to test the nanoprobe 
on healthy endothelial cells for comparison.   
 
The doses of glycogen nanoprobe for in vivo use should be optimized to match the effects of 
Omniscan due to the promising data obtained during in vitro experiments. Also, of all current 
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nano-sized materials in biomedical research, units with theranostic potential have been 
proposed to be of higher value, such as described by Wang and colleagues for instance (78). 
After optimizing the nanoprobe doses for in vivo use, it should be implemented in other 
animal tumor models besides subcutaneous ones to better study its detection of for instance 
brain tumors. If these studies are successful, it is further possible to attach fludeoxyglucose 
(FDG) to the nanoprobe (a glucose analogue) for nuclear medicine approaches, and also 
pharmaceuticals for theranostic use.   
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